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Jennifer Diane Beebe 
LANSOPRAZOLE AND ITS METABOLITES IN THE TREATMENT OF TNBC AND THE 
CONTRIBUTION OF ABCG2 TO CC-115 RESISTANCE 
Triple-negative breast cancer (TNBC) is a highly aggressive form of breast cancer 
with a dismal prognosis. Targeted therapies for breast cancer with expression of 
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth 
factor receptor 2 (HER2) are currently available; however, due to the lack of ER, PR, and 
HER2 in TNBC, targeted therapies are limited. While surgery and traditional 
chemotherapy remain the standard of care, development of a new treatment strategy 
for TNBC is needed to improve clinical outcomes. Fatty acid synthase (FASN) has been 
implicated as a metabolic oncogene and has given cancer cells a survival advantage by 
increasing NHEJ repair. Recently, it has been shown that FDA-approved proton pump 
inhibitors, used for the treatment of acid related digestive diseases, have antitumor 
effects. Here, I show that a metabolite of lansoprazole, 5-hydroxy lansoprazole sulfide, 
has increased potency over parent compound lansoprazole. 5-hydroxy lansoprazole 
sulfide inhibits FASN, leading to a decrease in PARP and NHEJ DNA repair activity in 
TNBC. Ultimately, this leads to an increase in DNA damage and cell death via apoptosis. 
These findings suggest that 5-hydroxy lansoprazole sulfide, as a metabolite of 
lansoprazole, may have better activity in suppressing TNBC cells and that 5-hydroxy 
lansoprazole sulfide may be developed as a therapeutic for TNBC treatment.   
Furthermore, due to the role of FASN in increasing NHEJ repair, we hypothesized 
that FASN played a role in resistance to CC-115, a dual mTOR/DNA-PK inhibitor currently 
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in clinical trials, by increasing DNA-PK activity. However, it was found that ABCG2, an 
ATP-binding cassette transporter, and not FASN, has a role in CC-115 resistance. ABCG2 
effluxes CC-115 from cancer cells, increasing resistance to treatment. Inhibition of 
ABCG2 by FTC or PZ39C8 led to accumulation of CC-115 within cells and sensitization to 
treatment. Therefore, ABCG2 status should be assessed to stratify patients into 
treatment groups, increasing the efficacy of CC-115 treatment. 
 
 Jian-Ting Zhang, Ph.D., Chair 
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CHAPTER 1: INTRODUCTION 
Section 1.A: Breast Cancer  
 The abnormal growth of cells that can spread to other areas of the body is called 
cancer. Cancer makes up a group of diseases that can affect all areas of the body. There 
are six hallmarks of cancer cells which distinguishes them from normal healthy cells. 
These hallmarks include: the ability of cells to evade apoptosis, self-sufficiency in growth 
signals, insensitivity to anti-growth signals, sustained angiogenesis, limitless replicative 
potential, and, the capability for tissue invasion and metastasis [1]. Over time, cells 
acquire DNA mutations which allow them to sustain these traits, leading to multiple 
types of malignancies in the body.  
 Breast cancer is the second most commonly diagnosed malignancy in women, 
after skin cancer, and has the second highest death rate in the U.S., behind lung cancer. 
It is estimated that 250,000 cases of invasive breast cancer are diagnosed a year and 
about 40,000 women die each year from breast cancer (breastcancer.org). Risk factors 
for breast cancer include weight, diet, alcohol use, smoking, age, family history, 
pregnancy, and breastfeeding. One genetic risk factor for breast cancer is a mutation in 
the breast cancer 1 and 2 genes (BRCA1 and BRCA2). BRCA1/2 are genes involved in 
activation of DNA repair processes. Mutations in these genes lead to an accumulation of 
DNA damage and neoplastic progression [2]. 2-6% of all breast cancers patients have a 
mutation in BRCA1 or BRCA2 [2].  While only 2-6% of breast cancers are affected by 
BRCA1/2, women who carry a mutation in one of these genes have a 40-57% lifetime 
risk of developing breast cancer [3]. This is a significant increase from about 12% of 
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women developing breast cancer in their lifetime without these mutations 
(breastcancer.org).  Therefore, having this mutation results in the need for earlier onset 
of mammograms and regular breast exams.  
Upon a breast cancer diagnosis, survival is highly dependent on the stage at 
which the cancer is diagnosed and the histological grade of the tumor cells. The earlier 
the cancer is detected, the better the chance of survival. Stage 0 breast cancer indicates 
that the abnormal, or cancer cells, remain within the duct of the breast. With increasing 
stages, I-III, the tumor begins to grow and invade nearby tissues, including the lymph 
nodes. At stage III, breast cancer is more advanced and harder to treat than at lower 
stages. Once the tumor has spread to distant areas of the body, it is considered stage IV. 
With increasing stages, there is a decrease in 5-year survival rate. 5-year survival rates 
are as follows: stage 0-1, nearly 100%; stage II, 93%; stage III, 72%; and, finally, stage IV, 
22%. 
 The histological grade of a tumor is a measurement of how different tumor cells 
are from benign cells and explains the differentiation state of the tumor. The more the 
tumors resemble benign cells, the lower the grade. The grade becomes higher as tumor 
cells show more abnormal characteristics and increased growth rate [4]. In breast 
cancer, the grade of a tumor is determined by the degree of gland formation, the 
variability in the size and shape of cells, as well as the mitotic count [5]. Grade I tumors 
maintain a tubular structure, resembling normal ducts and are not growing rapidly. 
Grade II tumors are beginning to lose glandular structure and acquire an abnormal 
phenotype, with an increase in growth rate as compared to benign cells. Grade III 
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tumors are very abnormal and have a very high proliferation index [6]. Both stage and 
grade are taken into account when physicians develop a course of treatment. Typically, 
a higher-grade tumor will require a more aggressive and immediate treatment course. 
The stage and grade will also help to determine which patients will benefit from 
adjuvant chemotherapy and those that will not.  
Breast cancer progression typically occurs in stages. The first stage being ductal 
hyperplasia of the ductal epithelial. Eventually, this hyperplasia becomes atypical and 
cells begin to populate the luminal duct. This stage of breast cancer is known as ductal 
carcinoma in-situ. If left untreated the cancer cells will spread outside the duct to the 
surrounding breast tissue where it will be classified as invasive ductal carcinoma. Breast 
cancer then becomes metastatic when it has spread to distant areas of the body outside 
the breast [7, 8]. There are several genetic alterations that have been implicated in 
breast cancer progression including mutations in BRCA, ATM, TP53, PTEN, AKT, and 
PI3KCA [7, 9-12].  
Epigenetic changes also play a role in breast cancer progression. The main forms 
of epigenetic change that occur in breast cancer is DNA methylation or demethylation of 
CpG islands in gene promoter regions and histone modifications [13]. DNA methylation 
in the promoter region of a gene will shut off expression due to an inability of 
transcription factors to bind to these regions. On the other hand, demethylation of a 
promoter will allow for its expression. Hypermethylation of genes involved in apoptosis, 
cell cycle regulation (CCND2, CDKN2A), DNA repair (GSTP1, BRCA1), hormone mediated 
cell signaling, and tissue invasion and metastasis have been observed in breast cancer 
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[14, 15]. Hypomethylation has also been observed in MDR1, NOTCH1 and NAT1 [7, 13, 
16, 17]. Increased DNA methylation of promoter regions of the DNA has been shown to 
be a risk factor for developing breast cancer [18]. Furthermore, a distinct pattern of 
hyper- and hypo- methylation of specific genes has emerged in the progression from 
ductal hyperplasia to atypical hyperplasia to ductal carcinoma in-situ and finally to 
metastatic breast cancer [14, 19-21]. An increase in methylation occurs in genes such as 
APC and CDH1 during progression while there is a decrease in methylation of LINE1 
during progression [22, 23].  TNBC specifically, is associated with hypermethylation of 
CD44, CDKN2B, RB, and p73, and hypomethylation of GSTP1, MSH2, TWIST1, DLC1, 
MSH6, and ID4 [24]. Additionally, an analysis of TNBC methylated regions showed that 
the hypomethylated profile was associated with better survival within the first 5 years 
compared to hypermethylated profile being associated with worse prognosis [15].  
Another form of epigenetic change, that has not been studied as extensively in 
breast cancer, is alterations of histones by post-transcriptional modifications. 
Acetylation or methylation of histones can lead to open or closed DNA, allowing for 
transcription or repressing transcription of genes [25]. Studies in breast cancer cell lines 
compared to non-cancerous cells lines have shown an increase in H3K4ac and H3K4me 
in TNBC potentially suggesting increased metastatic potential [26]. A genome-wide 
analysis of histones, their modifications, and their location has provided information on 
histones, modifications, and genes at specific sites that may be involved in cancer 
initiation and progression [27]. Further study in the epigenetics of breast cancer may 
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yield new treatment strategies and help to divide breast cancer into specific treatment 
groups.   
 Using DNA microarrays, breast tumors have been divided into four main distinct 
subtypes of breast cancer [28]. These subtypes correspond to histological grade of 
tumors and clinically observed features. These distinct features have been shown to 
influence patterns of response to different treatment strategies. Therefore, the subtype 
of breast cancer will help to determine course of treatment as well as patient prognosis. 
The main subclasses of breast cancers are luminal, which is broken up into luminal A and 
B, human epidermal growth factor receptor 2 (HER2) positive, and triple-negative 
(TNBC) breast cancer [29]. Microarray data revealed that luminal type tumors express 
luminal cytokeratins and other markers of epithelial cells. One the other hand, TNBC do 
not express ER, PR, or markers of luminal epithelial cells but several express basal 
cytokeratins such as CK5, and increased growth factor receptor expression [28]. 
Furthermore, microarray comparative genomic hybridization classified basal-like tumors 
as having an increased copy-number variation, but also low-level copy-number gains. 
This indicates more genetic instability because there are increased copy-number of 
genes throughout the genome that do not occur in the same pattern between samples 
[30, 31]. In contrast, luminal B and HER2 type had high level amplifications at specific 
gene sites [30].  
The most common type of breast cancer is luminal A breast cancer, comprising 
about 50-60% of all breast cancer cases. Luminal A cancers are typically characterized by 
high levels of estrogen receptor (ER) and/or progesterone receptor (PR) and are known 
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to grow slower than other subtypes, classifying them as low-grade tumors [32]. The 
majority of luminal B breast cancers are ER-positive and some express HER2. Luminal B 
cancers differ from luminal A by a marked increase in proliferative ability and increased 
expression of growth receptors [33]. Luminal B cancers are tumors with intermediate to 
high-grade differentiation, and make up about 15-20% of all breast cancers [34].  A third 
subset of breast cancer is the HER2-positive breast cancers. HER2-positive tumors make 
up 15-20% of all breast cancer cases and are high-grade breast cancers [34].  Lastly, 
TNBC is characterized by a lack of ER, PR, and HER2. TNBC makes up about 10-20% of 
cancer cases and involves high-grade tumors [34]. 
Treatment and outcomes of the different subtypes of breast cancer largely 
depends on the stage of the cancer and the molecular characteristics described above. 
Breast cancer is treated with a combination of surgery, radiation, chemotherapy, and 
targeted chemotherapy. Surgery removes the bulk of the primary tumor and nearby 
lymph nodes. Some patients will receive neoadjuvant chemotherapy, or chemotherapy 
prior to surgery, to shrink the tumor and to help prevent micro-metastasis while others 
will not require this treatment. Standard chemotherapy is usually administered 
intravenously, to ensure systemic drug delivery, and affects the entire body. Commonly 
used chemotherapeutic drugs include: alkylating agents, plant alkaloids, antitumor 
antibiotics, antimetabolites, and topoisomerase inhibitors. Many chemotherapies aim to 
cause DNA damage, or cell cycle arrest, ultimately leading to cancer cell death. 
Chemotherapies are very toxic to the body and come with many adverse side effects 
such as nausea, vomiting, appetite change, hair loss, fatigue, and increased risk of 
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infection. Targeted chemotherapies aim to identify ways in which cancer cells are 
different from benign healthy cells. These therapies utilize these differences to treat 
cancer. While targeted therapies still have side effects, they tend to be less severe than 
those observed with traditional chemotherapy [35, 36].  
Luminal A breast cancer has a very good prognosis. The rate of relapse in 
patients with luminal A breast cancer is lower than in all other subtypes of breast cancer 
[34]. Due to the high expression of the ER, these types of tumors can be treated with 
hormone therapy. Activation of ER in luminal A tumors leads to expression of genes 
involved in proliferation as well as cell survival [37]. Blocking this pathway, by blocking 
the ER itself or inhibiting estrogen production, has shown to be an effective treatment 
strategy for luminal A cancers. While luminal A breast cancer generally has a good 
prognosis and responds to hormone therapy, luminal B breast cancers are less 
responsive to hormone therapy. It has been suggested that luminal B cancer is estrogen 
independent due to a switch to different growth factor receptor pathways such as EGFR, 
IGF, or PIK [38]. Activation of these other pathways provides luminal B cancers with 
survival and growth advantages that are not affected by hormone therapy. Luminal B 
cancers have a slightly worse prognosis, and an increased recurrence rate as compared 
to luminal A breast cancers. This increase in relapse over luminal A is observed only in 
the first 5 years. Treatment for luminal B cancers differs from luminal A in that these 
tumors have a better response when given neoadjuvant chemotherapy, while there is 
no added benefit of neoadjuvant chemotherapy in luminal A breast cancer [34, 39].  
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HER2-positive breast cancers are so-named due to the overexpression of HER2. 
HER2 is a member of a family of four proteins that belong to the ErbB lineage of 
proteins. These proteins are a family of receptor tyrosine kinases which play a role in 
cell growth, survival, and proliferation [40]. The four members of this family are 
EGFR/ERBB1/HER1, HER2/ERBB2, HER3/ERBB3, and HER4/ERBB4 depicted in Figure 1. 
Typically, these four family members bind their ligand forming homo- and heterodimers, 
leading to activation of downstream signaling pathways including PI3K, JAK/STAT, and 
MAPK [41]. However, HER2 does not bind any known ligand and does not normally form 
homodimers. HER2 becomes active by binding to other family members that have been 
activated by ligand [40]. Overexpression of HER2 has been shown to lead to the 
formation of a functional HER2 homodimer [42]. HER2 gene amplification is the cause of 
HER2 overexpression 90% of the time in this subset [43]. This leads to a 40-100-fold 
increase in HER2 expression [44, 45]. HER2 type cancers without targeted treatment 
have a very poor outcome [34]. Luckily, trastuzumab, a monoclonal antibody targeting 
HER2 has been developed and has significantly improved the overall prognosis for HER2-
positive tumors [46]. Adjuvant trastuzumab alone reduced recurrence by 50% [47]. 
HER2-positive cancers are therefore treated with anthracycline chemotherapy in 
combination with trastuzumab.  
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Figure 1: ErbB signaling – The ErbB receptor family signals by binding their respective 
ligands and forming homo- and heterodimers. HER2 does not bind any ligand and 
becomes active by binding to other family members that have bound ligand. Typically, 
HER2 does not form an active homodimer but it has been shown that overexpression of 
HER in cancer can lead to signaling. The ErbB family of receptors, upon dimerization, 
leads to activation of several signaling pathways including PI3K, MAPK, and JAK/STAT 
increasing proliferation, survival, differentiation, and migration [41, 48, 49]. 
 
In contrast, TNBC does not express ER, PR, or HER2, making targeted treatment 
difficult at present. It does not respond to hormone therapy or HER2 targeted therapies. 
Additionally, very few mutations occur across TNBC. Two common mutations are p53 
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and PI3KCA [50]. TNBC has also been associated with an increase in EGFR, however, 
clinical trials using EGFR inhibitors in the treatment of TNBC have shown that only a very 
small percentage (0-3%) of patients responded to gefitnib and erlotinib treatment [51, 
52]. TNBC has the worst prognosis of all cancer subtypes and has the highest mortality 
rate within the first 3-5 years of diagnosis. The mainstay treatment for TNBC is currently 
a mix of chemotherapies with varying responses. A subset of TNBC patients are those 
with BRCA mutations. Patients harboring a BRCA1/2 mutation will have a TNBC 
phenotype 75% of the time [53]. There are two main pathways utilized by cancer cells to 
overcome DNA DSBs. The first, homologous recombination, occurs during DNA synthesis 
and is controlled by BRCA1/2 [54]. The second, NHEJ, can occur throughout the cell cycle 
but is an error prone method for DNA repair [55].  Due to the role of the BRCA genes in 
DNA repair, these patients are treated with DNA damaging agents, that ultimately lead 
to accumulation in DNA DSBs, leading to synthetic lethality. Studies have shown that 
neoadjuvant administration of cisplatin, a DNA damaging drug, leads to complete 
pathological response in a high number of patients with these mutations [56]. While this 
subset of TNBC responds well to chemotherapy, others do not and have no other 
treatment options. For this reason, there is significant interest in determining new 
treatment strategies for TNBC to improve patient health and prognosis. 
 
Section 1.B: Fatty Acid Synthase 
 In 1989, OA-519 was identified as a prognostic factor in breast cancer. Patients 
who expressed OA-519 were 4 times more likely to have recurrence of tumors and 
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metastasis [57]. There was an even greater chance of recurrence and metastasis when 
high expression was observed in estrogen receptor negative breast cancer. OA-519 
staining in prostate cancer increased with increasing stage and grade of tumors, while 
no OA-519 staining was observed in benign prostate tissue [58]. Further studies showed 
that OA-519 was a good prognostic factor for breast, ovarian, and prostate cancers [59-
61]. In 1994, OA-519 was identified as fatty acid synthase [62]. Since then, FASN 
overexpression has been observed in many types of cancers, including breast, prostate, 
ovarian, thyroid, colorectal, pancreatic, hepato-cellular carcinoma, lung, melanoma, 
bladder and stomach [63]. Furthermore, not only is FASN overexpressed, it has also 
been shown, using [14C] glucose, that 93% of all esterified fatty acids in cancer cells 
where made by de novo synthesis [64]. This would indicate that FASN is playing a major 
role in cancer cells.  
In the presence of a high carbohydrate diet, glucose derived from these 
carbohydrates is converted to pyruvate during glycolysis. Pyruvate is transported to the 
mitochondria where it is converted to acetyl-CoA by pyruvate dehydrogenase and is  
utilized in the citric acid cycle to produce adenosine triphosphate (ATP) and 
nicotinamide adenine dinucleotide (NADH) [65]. NADH then releases H+ to the electron 
transport chain to produce an electrochemical proton gradient that can be utilized to 
drive the formation of ATP, an energy storage molecule. When there is an excess of 
acetyl-CoA, it can be converted to citrate and shuttled back to the cytoplasm where it 
may be utilized for lipogenesis [66]. Lipogenesis is the process of forming fatty acids 
through FASN which can be stored as triglycerides or used in making other cellular lipids 
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[67]. Triglycerides can later be broken down by fatty acid b-oxidation to produce energy 
during times of low glucose supply [68]. Figure 2 depicts how glucose is taken up and 
utilized by the cell to produce energy in the presence and absence of oxygen as well as 
how glucose can be used to form other molecules required by the cell such as ribose-5-
phosphate, NADPH, and, lipids.   
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Figure 2: Overview of cellular metabolism – Cells take up glucose and shuttle it through 
several different pathways. In normal cells glucose is taken up by the cells and 
converted to pyruvate through glycolysis. The Pyruvate is then utilized in the citric acid 
cycle, or TCA, to produce ATP in the presence of oxygen. Normal cells can also perform 
lactic acid fermentation when oxygen is not available. Glucose can also move through 
the pentose phosphate pathway producing ribose-5-phosphate, precursor to the 
nucleotides, and NADPH, which can be used as a reducing agent. Excess Acetyl-CoA can 
be transported back to the cytoplasm in the form of citrate. Citrate is then converted 
back to Acetyl-CoA and can be used in the biogenesis of fatty acids by FASN. In cancer 
cells even in the presence of oxygen there is an increase in lactic acid fermentation, 
pentose phosphate pathway, and FASN [65-67, 69].  
 
The de novo synthesis of 16-carbon palmitate is carried out by fatty acid 
synthase (FASN). In humans, FASN is a 270 kDa homodimeric enzyme made up of seven-
domains. FASN is the only protein in the body capable of synthesizing de novo fatty 
acids [70] from acetyl-CoA, malonyl-CoA, and NADPH. These starting molecules are used 
in the formation of palmitate in the following reaction [71]: 
Acetyl-CoA + 7 Malonyl-CoA + 14(NADPH + H+) ® 
Palmitate + 8 CoA-SH + 14 NADP+ + 6H20 
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The formation of palmitate occurs as a series of reactions orchestrated by the seven 
domains of FASN: acyl carrier protein (ACP), b-ketoacyl synthase (KS), malonyl/acetyl 
transferase (MAT), b-ketoacyl reductase (KR), b-hydroxylacyl dehydratase (DH), enoyl 
reductase (ER), and thioesterase (TE) domain [71, 72]. Each cycle of the reaction 
elongates the growing carbon chain by two carbons. The first step in this process is the 
transfer of the acetyl group from acetyl-CoA to the ACP and malonyl from malonyl-CoA 
to ACP by MAT. Then, KS catalyzes the condensation of acetyl-ACP and malonyl-ACP, 
releasing one ACP and a CO2 molecule. 
Acetyl-ACP + Malonyl-ACP ® b-ketoacyl-ACP + CO2 + ACP 
KR then reduces the 3-keto, using NADPH, to a hydroxyl group. 
b-ketoacyl-ACP + NADPH ® D-3-hydroxyacyl-APC + NADP+ 
A dehydration occurs by DH creating a double bond and releasing H2O. 
D-3-hydroxyacyl-APC ® trans-D2-enoyl-ACP + H2O 
A second reduction occurs using NADPH and is catalyzed by ER. 
trans-D2-enoyl-ACP + NADPH ® Butyryl-ACP + NADP+ 
This cycle will continue until the carbon chain reaches 16 carbons in length, at which 
point the TE domain hydrolyzes the thioester bond between the fatty acid and the ACP, 
releasing the free fatty acid. From there, palmitate can be used in a variety of cellular 
functions. The entire cycle is outlined in Figure 3. 
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Figure 3: Reactions of Fatty Acid Synthesis – Fatty acid synthesis occurs in a series of 
reactions that results in the release of 16 carbon palmitate. FASN starts with the 
transfer of acetyl-CoA and malonyl-CoA to the APC domains in the FASN dimer, 
catalyzed by MAT. Malonyl-CoA is made from acetyl-CoA by ACC. KS condenses the 
acetyl and malonyl groups into a single chain, releasing CO2. Then, through two 
reduction reactions and a dehydratase, two carbons are added to the growing chain. 
The new growing chain will take the place of acetyl-CoA in the beginning of the reaction, 
and two more carbons will be added each cycle until the chain reaches 16 carbons in 
length. At this point, the TE domain of FASN will cleave the new fatty acid from the 
enzyme, releasing it into the cytoplasm.  
 
After palmitate is released from FASN, it can be used in a variety of ways. As 
discussed above (Figure 2), fatty acids can be stored in the form of triglycerides in the 
liver and adipose cells for use during times of low glucose [73]. Palmitate can also be 
used to modify different proteins. Palmitate can covalently and reversibly bind to 
cysteine residues within proteins in a process called palmitoylation, catalyzed by protein 
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palmitoyltransferases [74]. Palmitoylation of proteins increases their hydrophobicity and 
interaction with cellular membranes. The reversibility of this modification allows for 
shuttling modified proteins between cellular compartments and regions of the plasma 
membrane [75, 76]. Another function of palmitoylation is to target proteins to lipid 
rafts, where they are involved in many different types of cell signaling. Inhibition of this 
modification prevents localization and function of these proteins [74]. Furthermore, 16-
carbon palmitate can be elongated or desaturated by other cellular enzymes. These 
products may then be used in cellular lipids such as phospholipids or cholesterol esters 
[77, 78]. 
In humans, fatty acid synthesis is a highly regulated pathway. Expression of FASN 
is controlled by the sterol regulatory element-binding protein-1c (SREBP-1c) 
transcription factor [79]. An increase in hormone insulin stimulated by glucose in the 
blood enhances transcription of SREB-1c, leading to an increase in FASN [80, 81]. 
Conversely, low glucose stimulates glucagon production, suppressing SREBP-1c 
transcription [82]. SREBP-1c is not only regulated at the transcription level, but also post 
translationally. SREBP binds to SREBP-cleavage-activating protein (Scap) in the 
endoplasmic reticulum membrane. In the endoplasmic reticulum Scap acts as a sensor 
for sterol content. Cholesterol binds to Scap changing its conformation and allowing it to 
bind to insulin-induced gene 1 (Insig1), retaining the complex in the endoplasmic 
reticulum [83]. This means SREBP cannot activate transcription. When sterols are 
depleted in cells, Scap will not bind to Insig1, allowing the SREPB-Scap to be transported 
to the Golgi [84]. Here, there are two sequential proteolytic cleavage events that result 
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in the release of the transcription factor domain from the membrane. SREBP is now 
transported into the nucleus to begin transcription [84]. 
 Another regulator of FASN is the enzyme acetyl-coenzyme A carboxylase (ACC). 
ACC is the rate limiting step for fatty acid synthesis because it is responsible for the 
conversion of 2 carbon acetyl-CoA to 3 carbon malonyl-CoA [69]. As mentioned above, 
malonyl-CoA is one of the starting materials required for FASN. ACC uses ATP to convert 
acetyl-CoA to malonyl-CoA using a carbon from CO2 [71]. ACC activity is controlled by 
allosteric effectors and phosphorylation events. Citrate levels in the cytoplasm can up-
regulate ACC while free CoA and fatty acyl-CoA, such as malonyl-CoA and palmitoyl-CoA, 
can down-regulate ACC activity [85]. AMP-activated protein kinase (AMPK), is a cellular 
energy sensor that tells cells to inhibit anabolic processes and conserve energy when 
ATP is low [86]. AMPK phosphorylates ACC, leading to its inhibition. When AMPK is 
turned off by low levels of AMP and high levels of ATP, ACC is dephosphorylated, 
becoming active again [87]. In this way, FASN is highly regulated by availability of 
nutrients within the cell. 
Due to FASN regulation by nutrient availability, in an adult consuming a common 
diet today, FASN activity is not required. Today’s diet high in fats reduces the need for 
FASN [88]. Weiss et al. noted that in some cases of a prolonged fat-free diet, 
researchers were able to observe an increase in FASN activity in human tissues; but, 
with the modern diet, normal cells receive enough fatty acids, with a few exceptions 
[88]. Expression of FASN has been observed in mostly hormone sensitive cells [89], liver 
cells [90, 91], and adipose cells. FASN supplies fatty acids in the breast during lactation 
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[92], and FASN is linked to endometrial cell proliferation during the menstrual cycle [93]. 
Additionally, FASN is required during embryogenesis. When mice harboring FASN+/- 
were bred, they did not produce FASN-/- mice. Furthermore, FASN-/- mice produced in 
the lab died before implantation [94]. De novo FA synthesis has been shown to be active 
during embryogenesis and one of its known functions is in lung development, where 
fatty acids are used to make lung surfactant [95]. At 20 weeks gestation FASN is present 
in proliferative epithelial cells throughout different body systems [89]. 
 
Section 1.C: FASN and Cancer 
 While normal tissues do not have high expression of FASN and do not depend on 
de novo fatty acid synthesis for survival, this may not be the case for cancer cells. 
Another difference in cancer cells is their preference to use lactic acid fermentation as a 
source of energy, even in the presence of oxygen. Normal tissues use the more efficient 
energy production of oxidative phosphorylation in the mitochondria when oxygen is 
present [96]. This phenomenon of using an inefficient method of energy production in 
cancer cells is known as the Warburg effect because it was first observed in the early 
1920s by Otto Warburg and colleagues that cancer cells increased uptake of glucose 
compared to benign cells [97]. While oxidative phosphorylation is a more efficient way 
to produce ATP per molecule of glucose, lactic acid fermentation occurs much more 
rapidly and has the ability to produce comparable levels of ATP in a given time frame 
when glucose uptake is increased [98]. The question remains, why do cancerous cells 
use this method of energy production when oxidative phosphorylation is so much more 
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efficient? One explanation for the Warburg effect is that cells take up more glucose as 
an adaptation mechanism for supporting the biosynthetic requirements of proliferation. 
In this way, the glucose can be used as a source for anabolic processes, such as 
generation of nucleotides, lipids, and proteins [96]. These are building blocks which are 
required for rapid cellular divisions and, as stated above, 93% of esterified fatty acids in 
cancer cells are made by de novo fatty acid synthesis. This highlights the need for FASN 
activity. Additionally, glucose flux through the pentose phosphate pathway leads to the 
production of ribose-5-phosphate, a precursor for nucleotides, and NADPH, an 
important molecule for reduction reactions and for detoxification of reactive oxygen 
species (ROS) [99, 100]. These pathways are illustrated in Figure 2. 
 In cancer cells, a large part of the synthesized fatty acids are esterified to 
phospholipids in cellular membranes [62, 101]. This indicates FASN is utilized in cancer 
cells to produce new membranes for rapidly dividing cells. FASN overexpression and use 
by cancer cells may be explained by a couple different mechanisms. An increase in 
growth factor receptor signaling and hormones have been implicated in SREBP-1c 
stimulation and FASN transcription [102, 103]. Growth factor receptors such as EGFR 
can increase FASN transcription by activating phosphatidylinositol-3 kinase (PI3K)-Akt 
signaling pathway and mitogen activated protein kinase (MAPK)/extracellular signal-
regulated kinase (ERK1/2) pathway [104, 105]. Additionally, commonly observed 
mutations in this pathway, such as the loss of phosphatase and tensin homologue 
(PTEN), causes activation of PI3K/Akt and correlates with FASN overexpression [106]. 
While this pathway has been shown to regulate FASN, FASN is also involved in 
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expression of receptors in this pathway. For example, FASN is responsible for regulating 
EGFR, HER2, and HER4 expression [107-109]. This creates a complicated coregulatory 
loop in which HER family members and FASN regulate each other. Steroid hormones can 
activate similar pathways, leading to FASN expression. Another mechanism of 
overexpression of FASN occurs by copy number gain of the FASN gene, which has been 
observed in prostate cancer [110].  
 FASN overexpression in cancers not only demonstrates prognosis, but also 
correlates with cancer stage and aggressiveness of the tumor [111]. With increasing 
stage, there is an increase in FASN staining within the tumor. Specifically, in terms of 
breast cancer, FASN is associated with clinically aggressive tumor behavior and growth 
[107]. In fact, there is evidence supporting the role of FASN as an early event in 
tumorigenesis. While FASN is not found in normal tissues, those that are pre-cancerous 
or early cancerous lesions have shown expression of FASN in breast, prostate, colon, 
esophageal, and stomach tissues [112-115]. FASN has been considered a “metabolic 
oncogene,” giving cells survival advantages in the hypoxic and acidic microenvironment 
observed in most solid tumors [116]. Overexpression of FASN in non-tumorigenic breast 
cells led to an increase in cell growth, HER2 expression, proliferation, and anchorage 
independent growth, which is indicative of tumorigenesis [111, 117]. Shutting off FASN 
in MCF10A transformed cells lines reversed tumorigenicity and returned cells to a more 
benign state [118]. Overexpression of FASN in immortalized prostate cells led to an 
increase in invasive tumors as compared to those lacking FASN expression [119]. FASN 
may be contributing to the tumorigenic phenotype in a few different ways. FASN can 
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affect different signaling pathways within cells. FASN overexpression leads to an 
increase in activation of HER1, HER2, and HER3, which has been associated with cancer 
[108, 117]. FASN overexpression leads to the stabilization of Wnt/b-catenin by 
increasing palmitoylation of Wnt-1 [119]. Wnt/b-catenin has been implicated in many 
different types of cancer by promoting tumorigenesis, proliferation, and stem cell 
maintenance [120, 121].   
 FASN has also been implicated in resistance to chemotherapeutics in cancer 
cells. Previously it was found in our lab that FASN was overexpressed in a doxorubicin 
selected breast cancer cell line and that ectopic overexpression in breast cancer cells led 
to an increase in resistance to doxorubicin [122]. In resistant hepatocellular carcinoma 
cells, FASN inhibition can sensitize cells to taxane treatment in vitro [123]. FASN 
inhibition was also capable of re-sensitizing breast cancer cells to trastuzumab 
treatment [62]. Furthermore, FASN is associated with resistance to gemcitabine and 
radiation in pancreatic cancer and radiation in nasopharyngeal carcinoma [124, 125]. 
These studies indicate that FASN is playing a role in resistance to a variety of anticancer 
agents.  
There are a few proposed mechanisms as to how FASN is leading to drug 
resistance. One possible mechanism is FASN inhibiting apoptosis and caspase-8 
activation after exposure to drug by inhibiting production of TNF-a and ceramide, 
upstream activators of caspase 8 [126]. Rysman et al. found that tumor cells that were 
resistant to chemotherapy had an increase in FASN. This increase correlated with an 
increase in saturated fatty acids in the membrane, resulting in less fluidity, as indicated 
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by movement of green fluorescent dye and decrease in permeability to doxorubicin. 
Inhibiting ACC with soraphen A or knocking down ACC or FASN returned cells to a more 
fluid permeable state, restoring chemo-sensitization [127]. Therefore, FASN could lead 
to resistance by changing cellular membrane dynamics reducing drug penetrance. A 
previous paper from our lab has shown that FASN increases activity of the DNA repair 
mechanism, non-homologous end joining (NHEJ) [128]. Repair of DNA damage by NHEJ 
contributes to resistance to DNA damaging agents [128]. Specifically, FASN leads to an 
increase in PARP expression and this increase allows for a greater recruitment of Ku 
proteins to sites of DNA damage and an increase in NHEJ repair [128]. This increase in 
repair has been shown to increase resistance to DNA damaging agents. 
 
Section 1.D: Inhibitors of FASN 
Due to the role of FASN in cancer, its association with a more aggressive form of 
cancer, and chemo-resistance, many studies have been conducted to identify novel 
inhibitors for this pathway. In breast cancer cells, silencing of FASN led to mitochondrial 
impairment and induction of apoptosis [129]. In colorectal cancer cells, knockdown of 
FASN inhibited cell proliferation, migration, and invasion [130, 131]. Proliferation and 
metastasis were also suppressed in gastric cancer upon suppression of FASN [132]. In 
prostate cancer, knockdown of FASN led to growth inhibition and induction of apoptosis 
while having no effect on non-malignant fibroblasts [133]. Furthermore, Chen et al. 
showed that direct injection of FASN siRNA into prostate cancer xenograft reduced 
tumor growth [134]. A genome-wide analysis of expression changes revealed that 
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silencing FASN led to a decrease in genes involved in lipid metabolism, glycolysis, the 
TCA cycle, and oxidative phosphorylation. Additionally, knockdown of FASN led to an 
upregulation of genes involved in cell cycle arrest and death receptor mediated 
apoptotic pathways [135]. Introduction of FASN inhibitors had synergistic effects with 
both docetaxel and paclitaxel in an in vitro model of breast cancer [136, 137]. In an in 
vivo xenograft model of non-small cell lung cancer paclitaxel and FASN inhibition had a 
potent synergistic effect [138]. These studies indicate that targeting FASN 
pharmacologically may be a way to specifically target cancers cells while having limited 
adverse effects on normal tissues. 
Due to the number of enzymatic reactions that FASN controls, there are several 
ways in which FASN has been targeted. One of the first small molecule inhibitors of 
FASN was cerulenin. Cerulenin is a compound isolated from Cephalosporium caerulens, 
which irreversibly binds to KS domain of FASN, preventing the condensation reaction of 
acetyl-APC to the growing chain with malonyl-APC [139]. In breast cancer cells and 
promyelocytic leukemia cells, cerulenin inhibited cell growth; however, supplementing 
treatment with high levels of palmitate, the end product of FASN, was able to reverse 
this growth inhibition [62, 140]. This indicates that end product starvation has 
deleterious effects on cancer cells. Inhibition by cerulenin reduced growth and induced 
apoptosis in melanoma cells [141], breast cancer cells [142], colon cancer cells [143] and 
prostate cancer cells [144]. Cerulenin treatment in a xenograft model of ovarian cancer 
led to regression of established tumors. Furthermore, cerulenin prevented liver 
metastasis in a murine model of colon cancer [143]. Unfortunately, the highly reactive 
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cysteine epoxide group prevents cerulenin from being clinically developed. Several 
analogs of cerulenin have been made, including C75, C93, C247, and, FAS31 to increase 
potency and limit adverse side effects [145]. C75 has been shown to interact with 
several different FASN domains, including KS, KR, ER, and TE. While this promiscuity 
does not make C75 good for clinical trials, it has shown to have antitumor activity in 
xenograft models of breast, prostate, ovarian and mesothelioma cancers [146]. 
Epigallocatechin-3-gallate (EGCG), a compound found in green tea, inhibits the 
KR domain of FASN [147]. EGCG not only inhibits FASN but has inhibitory effects on HIF-
1-alpha and PI3K/Akt [148]. EGCG showed activity against prostate cancer cells [149]; 
however, a randomized phase II study of the protective effect of EGCG at 600 mg/day 
showed no significant difference of FASN or Ki-67 levels in prostate tissue [150]. 
GSK2194096 is another inhibitor of the KR domain [151] which was shown to have 
activity against non-small cell lung cancer [152]. Fasnall, a recently developed FASN 
inhibitor targets the co-factor binding site [153]. This inhibitor had anti-proliferative 
activity and induced apoptosis in breast cancer cells.  
FDA-approved orlistat, a pancreatic lipase inhibitor, was discovered to also 
inhibit the TE domain of FASN [154]. Orlistat has been shown to inhibit proliferation and 
to induce apoptosis in prostate cancer and melanoma in vitro and in vivo [154, 155]. 
Orlistat also led to regression of tumors in gastric cancer xenograft model and extended 
survival times [156]. Due to poor bioavailability, low solubility, weight loss as a side 
effect, and low stability, orlistat cannot be used as a cancer treatment [157, 158]. 
Weight loss in these mice is a side effect due to lack of specificity of orlistat which can 
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inhibit the breakdown, and, therefore, the absorption of fats after eating [159]. Many 
analogs have been synthesized but to date none have been proven effective [160-163].  
Other FASN inhibitors have been reported, including triclosan [164], which inhibits ER of 
FASN, and a variety of natural products [165-173]. Thus far, of these novel inhibitors, 
only TVB2640 has made it into clinical trials. Currently, TVB2640 is in a variety of phase I 
and phase II clinical trials for the treatment of many different cancers by itself and in 
combination with other agents [174-177]. 
Recently, our lab has taken an interest in identifying previously FDA-approved 
drugs that have inhibitory activity against FASN. Many drugs fail to make it into clinical 
trials due to poor pharmacokinetic properties. Using currently approved FDA drugs 
allows for the evaluation of compounds that have known favorable pharmacokinetic 
properties. In-silico screening was used to identify possible inhibitors of FASN and 
proton pump inhibitors (PPIs) were shown to have inhibitory effects on the TE domain 
of FASN [178]. PPIs are used as the standard of care for treating acid-related diseases 
like esophagitis, nonerosive reflux disease, and peptic ulcer disease; they are even used 
in combination with antibiotics in the treatment of Helicobacter pylori [179]. PPIs are 
prodrugs that are membrane permeable, and, once they are absorbed into gastric 
parietal cells, the PPI undergoes acid-base reactions, producing a sulfenic acid and/or 
sulfonamide. This compound can then bind irreversibly to the cysteine residues on the 
H+/K+ ATPase proton pumps [180]. This prevents the secretion of acid into the gastric 
lumen until new pumps can be made by cells [181]. The current FDA approved proton 
pump inhibitors include lansoprazole (Prevacid), omeprazole (Prilosec), pantoprazole 
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(Protonix), rabeprazole (Aciphex), esomeprazole (Nexium), and dexlansoprazole 
(Kapidex). Studies on the safety of long-term use of PPIs have shown that they are well 
tolerated and safe with very few adverse side effects [182].    
While our lab was the first to identify PPIs as FASN inhibitors, there have been 
many observations on PPI’s use in cancer treatment. Early studies of solid tumors in in 
vivo mouse models of melanoma, colon, breast, and ovarian cancer cells, showed that 
combining chemotherapy (cisplatin, 5-FU, and vinblastine) with pretreatment of 
omeprazole, esomeprazole or pantoprazole, increased sensitivity to treatment [183]. 
Treatment of osteosarcoma cells with lansoprazole decreased invasiveness and 
migration abilities of these cells [184]. While the mechanism of action for decreased 
invasion and migration is unknown this could be due to FASN inhibition. Lansoprazole 
treatment, in combination with reverse transcriptase inhibitor Efavirenz, decreased 
proliferation and increased cellular apoptosis in metastatic melanoma [185]. 
Additionally, treatment of melanoma with suboptimal doses of paclitaxel and 
lansoprazole induced sensitivity to treatment [186]. The use of omeprazole in human B-
cell tumors led to a decrease in growth and a caspase independent apoptotic event 
[187]. This event was mediated by early reactive oxygen species (ROS), alkalization of 
lysosomal pH and increased cytosolic acidification, and membrane permeabilization of 
cellular organelles [187]. Esomeprazole inhibited proliferation of melanoma cells and 
increased survival of a xenograft melanoma mouse model [188]. Treatment of xenograft 
models of breast and prostate cancer with pantoprazole alone did not affect tumor 
growth rate but combined treatment with docetaxel caused growth delay more than 
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single agent docetaxel alone [189]. Furthermore, treatment of mouse mammary 
carcinoma cell line, EMT6, and human adenocarcinoma cell line, MCF7, with 
lansoprazole caused an increase in cellular penetrance of chemotherapeutic doxorubicin 
in multilayered cell culture and improved spatial distribution in in vivo models of tumor 
growth as indicated by biomarkers of drug toxicity in all areas of the tumor [190].  
Some of these observed effects of PPIs on cancer cells may be attributed to FASN 
inhibition, which causes changes in membrane structure and DNA repair, while others 
may be due to alternate effects caused by PPIs. A common occurrence in solid tumors is 
the acidification of the extracellular space resulting from the change in metabolic 
activity of cancer cells [191]. This acidic environment can lead to drug resistance by drug 
inactivation through protonation of the chemotherapeutic drug [192, 193]. The cells 
selected to survive in this acidic environment have activation of pH-regulating systems 
to prevent intracellular decreases in pH. Vacuolar-type H+ ATPase (vATPase) is a pH-
regulator that prevents acidification of the cytosol by pumping H+ out of the cell or into 
lysosomes within the cell [194]. Increased expression of vATPase has been shown to 
provide growth advantages and improve survival of cancer cells [195-197]. Inhibition of 
vATPase has become an attractive target, and PPIs not only inhibit H+/K+ ATPases, but 
also vATPase [198]. Inhibition of vATPase by PPI may lead to cancer cell acidification and 
cell death. Additionally, PPIs have been shown to be substrates of ABC efflux transporter 
P-glycoprotein and have the ability to inhibit its activity [199]. P-glycoprotein is known 
to efflux a variety of anticancer agents out of the cell, leading to multi-drug resistance 
[200]. Inhibition of P-glycoprotein by PPIs could be having an effect on cancer cells. 
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Based on all these observations clinical trials have been performed to evaluate the use 
of PPIs in cancer. 
A clinical study in companion animals showed that PPI treatment reversed 
chemo-resistance in lymphoma and solid tumors [201, 202]. There is currently a phase II 
clinical trial ongoing to evaluate the use of pantoprazole with docetaxel in men with 
prostate cancer [203, 204]. A completed phase II trial concluded that intermittent high 
doses of esomeprazole enhanced the effects of docetaxel and cisplatin in metastatic 
breast cancer patients [205]. There is also a phase II trial ongoing in TNBC to assess the 
use of omeprazole as a neoadjuvant therapy [206]. 
Studies in our lab as well as others have shown that not all proton pumps are 
equal when it comes to the treatment of cancer. Lugini et al. found that lansoprazole 
showed the highest antitumor effect when compared to other PPIs [207]. Due to the 
short half-life of PPIs in the body we hypothesized that not only parent compound but 
also the metabolites of certain PPIs have activity against FASN increasing antitumor 
effect. 
 
Section 1.E: CC-115 and NHEJ 
 The PI3K-related kinase family (PIKK) includes ataxia-telangiectasia mutated 
(ATM), ataxia-telangiectasia mutated related (ATR), hSMG1, DNA-dependent protein 
kinase (DNA-PK), and mammalian target of rapamycin (mTOR) [208]. This family of 
serine/threonine kinases regulates response to DNA damage and response to nutrients, 
regulating cell growth [208]. Specifically, as shown in Figure 4, DNA-PK plays an 
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important role in non-homologous end joining (NHEJ), a repair mechanism for DNA 
double strand breaks (DSBs) [209]. mTOR functions in the regulation of translation, cell 
proliferation, and cell survival (Figure 4) [210].  
DNA-PK catalytic subunit (DNA-PKcs) is required for repairing lethal DNA DSBs 
caused by oxidative and replicative stress, irradiation, and those caused by 
chemotherapeutics [216]. Ultimately, DNA repair mechanisms are utilized to allow 
cancer cells to overcome DNA DSBs associated with stress brought on by rapid 
proliferation as well as allow these cells to repair damage created by anticancer 
treatments leading to survival and resistance [217]. Studies have shown that knock 
down and pharmacologic inhibition of DNA-PK enhances chemo- and radio-sensitivity 
[218-220]. For this reason, efforts are currently being made to produce a drug that 
targets DNA-PK for use in the clinic.  
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Figure 4: Schematic of the DNA-PK pathway (A) and mTOR pathway (B) A) After 
sensing DNA DSBs ATM and DNA-PKcs phosphorylate H2AX signaling to the cell to repair 
the damaged DNA. This can occur in two ways: homologous recombination or NHEJ 
[211-213]. DNA-PK is a trimeric protein made up of Ku70, Ku80, and catalytic subunit 
DNA-PKcs. B) mTORC1/2 are activated downstream of growth factor receptor signals. 
Upon activation mTORC1 phosphorylates S6K, leading to its activation, and 4EBP1, 
leading to its suppression. mTORC2 leads to the activation of AKT, SGK-1, and PKCa 
[214, 215]. 
 
mTOR is activated downstream of the PI3K/AKT pathway and is involved in the 
regulation of cell growth, proliferation, and  survival [210]. mTOR is activated by signals 
from growth factor receptors, nutrients, and stress signals. Two functionally different 
complexes, mTORC1 and mTORC2, make up mTOR.  mTORC1 made up of raptor, 
PRAS40, Deptor and LST8, regulates the level of mRNA translation by modulating the 
activity of several translational components including 4EPB1 and p70S6 Kinase [215]. 
mTORC2 consists of rictor, SIN1, Deptor, Protor and LST8. mTORC2 activates AKT, 
Paxillin, and PKC-α through phosphorylation and regulates the actin cytoskeleton 
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through small GTPase Rac and Rho, which enhances cell survival and migratory ability 
[215]. Dysfunction of multiple points in the mTOR pathway has been associated with 
many types of cancer. For example, PI3K amplification and mutations, PTEN loss of 
function, RTK amplifications, and AKT mutations have all been implicated in promoting 
tumorigenesis through upregulation of this pathway [221]. Notably, mTOR is 
downstream of PI3K/AKT and has also been implicated in cancer. Therefore, mTOR is a 
good target for the development of anticancer drugs. Currently, there are a few drugs, 
VX-984, CC-115, and nedisertib, that are in clinical trials for use as a single agent and in 
combination with other therapies.  
Specifically, CC-115, which is a dual mTOR/DNA-PK inhibitor, is a triazole 
containing compound that was identified through structure-activity relationship studies 
[222]. Early studies showed that CC-115 binds to the ATP binding site with extensions 
into the catalytic pocket allowing for some specificity [222]. CC-115 is selective for 
mTOR and DNA-PK over closely related PIKK family members [223]. There are several 
ongoing clinical trials to test the efficacy of CC-115 in an array of different cancer types. 
Currently, there are phase I trials in squamous cell carcinoma of head and neck, Ewing’s 
osteosarcoma, chronic lymphocytic leukemia (CLL), neoplasm metastasis, and prostate 
cancer [224]. There is also a phase II trial in glioblastoma. Early findings in clinical 
efficacy of CC-115 in CLL patients showed that 7 of 8 patients had a decrease in 
lymphadenopathy, with 1 partial response and 3 partial responses with lymphocytosis 
[225]. Lymphocytosis, or a prolonged state of increased lymphocyte count, is a common 
occurrence after treatment with BCR/ABL inhibitors [226-228]. Lymphocytosis after 
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treatment does not affect progression free survival. In fact, CML patients with 
lymphocytosis had an increase in overall survival [226].    
While these early results in CLL show promise for further development of CC-
115, there is an observed variability in sensitivity to drug. In this study, 1 of the 8 
patients showed no decrease in lymphadenopathy and may be considered resistant to 
CC-115. Determining mechanisms of resistance to CC-115 will help to stratify patients 
into treatment groups for a more personalized approach to treating cancer and 
identifying new targets for cancer treatment.   
Recently, it has also been shown that fatty acid synthase (FASN) contributes to 
drug resistance by increasing NHEJ repair of DNA damage via facilitating recruitment of 
Ku proteins and increasing DNA-PK activity [229]. Thus, it is possible that FASN may 
contribute to CC-115 resistance by increasing DNA-PK activity. In this study, we tested this 
hypothesis using breast cancer cell models. However, resistance to CC-115 was not 
mediated through FASN but through ABCG2. ABCG2 contributes to CC-115 resistance by 
reducing CC-115 accumulation. Inhibiting ABCG2 using small molecule inhibitors was able 
to reverse CC-115 resistance. These findings suggest that CC-115 is a substrate of ABCG2 
and ABCG2 expression could play a role resistance to CC-115.  
 
Section 1.F: ATP-binding cassette transporters and drug resistance 
 There are many known molecular mechanisms of drug resistance. In particular, 
ATP binding cassette (ABC) transporters such as ABCB1, ABCC1, and ABCG2 are well 
known transporters that contribute to multidrug resistance by actively transporting drug 
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substrates out of cells using ATP [230]. Transport across a membrane requires a 
membrane transport protein. While some molecules, such as water, can diffuse through 
the phospholipid bilayer, this process can be accelerated by using membrane proteins. 
There are four main types of membrane transport proteins: ion channels, aquaporins, 
transporters, and ATP powered pumps. Transporters can be either passive or active. 
Passive transports move a molecule down its concentration gradient, from high to low. 
Active transporters move a molecule against the concentration gradient by coupling this 
movement to the movement of a molecule down its gradient. Active transporters can 
move both molecules in the same direction, symporter, or in opposite directions, 
antiporter. Ion transporters help to maintain gradients across cell membranes that lead 
to voltage gradients. The regulation of these gradients is important for signaling and 
allowing for activation of membrane proteins [231]. Aquaporins are bidirectional 
channels that transport water across the membrane due to osmotic pressure [232]. 
Lastly, ATP powered pumps utilize the energy released by ATP hydrolysis to move 
substrates across cellular membranes. ATP powered pumps can move substrates into, 
influx, or out, efflux, of cell as well as transporting into vesicles.  
 ATP-binding cassette pumps (ABC) are a family of ATP powered pumps that are 
exclusively exporters in humans [233]. The ABC family is broken up into 7 subfamilies, A 
to G. This family transports a variety of substrates, including metal ions, peptides, amino 
acids, sugars, and large hydrophobic compounds [234]. In normal physiology the efflux 
of these and other endogenous and exogenous toxins acts to protect cells. ABC family 
members are expressed in many different tissues where they can influence elimination 
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of substrates and limit drug absorption [235]. This is useful in eliminating drugs and their 
metabolites from the body and preventing negative effects caused by these compounds. 
ABC family members are expressed at the BBB where they help minimize the neurotoxic 
effects of toxins and drugs on the brain [236]. Unfortunately, these compounds can also 
work against given drugs by preventing their absorption into target tissues, as in the 
case of treating different types of cancer with chemotherapeutics.  
 P-glycoprotein, or MDR1/ABCB1, was the first ABC transporter to be identified in 
multi-drug resistance in cancer [237]. Early studies indicated that P-glycoprotein 
reduced drug accumulation within cancer cells and led to their resistance to several 
types of drugs. After the identification of P-glycoprotein, other family members began 
to emerge. One of these family members is ABCG2. ABCG2, also known as BCRP, was 
discovered in drug resistant breast cancer cells. ABCG2 was responsible for resistance to 
doxorubicin, daunorubicin, and mitoxantrone by reducing cellular accumulation of these 
chemotherapeutics [238]. While ABCG2 was identified in breast cancer cells, it plays 
major roles throughout the body.  
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Figure 5: ABCG2 dimerization and oligomerization allows for active transport of 
substrates across the membrane - ABCG2 utilizes the energy from ATP hydrolysis to 
move substrates across the phospholipid bilayer.  
 
 ABCG2 is a “half-transporter” in that it contains only one transmembrane 
domain and one NBD. Therefore, ABCG2 requires dimerization or oligomerization to 
form a complete complex [239]. Once the functional transporter is formed, it will bind 
ATP at the NBD and use the energy from ATP hydrolysis to efflux its substrates as shown 
in Figure 5. The efflux of materials by ABCG2 happens in many different areas of the 
body. ABCG2 is expressed in the kidneys, intestines, placenta, BBB, and in stem cells. In 
the kidneys, ABCG2 mediates urate secretion, and 10% of gout cases can be attributed 
to a mutation in ABCG2 [240]. The intestine’s job is to absorb nutrients and water from 
what we eat and drink. ABCG2 expression in the intestines plays a role in xenobiotic 
detoxification [241]. ABCG2 is highly expressed in the placenta and is believed to protect 
the fetus from harmful agents [238]. Expression of ABCG2 on the luminal surface of the 
CNS vasculature allows the endothelial cells to limit the permeability of toxins and drugs 
to the brain [242, 243]. ABCG2 also plays a role in maintaining progenitor cells and is 
considered a marker for these cells [243]. Expression of ABCG2 in progenitor cells allows 
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them to survive in hypoxic conditions by reducing heme and porphyin accumulation 
[244]. A change in expression of ABCG2 can have effects on the pharmacokinetics of 
substrate drugs. For instance, a decrease in ABCG2 expression, caused by a SNP, Q141K, 
carries an increased risk of adverse effects to a variety of drugs possibly due to an 
increase in absorption [245]. For this reason, expression of ABCG2, not only at a target 
tissue, but also in the intestines, endothelium, and BBB can affect the uptake of drug by 
tissues.  
 ABCG2 expression has been observed in many different types of cancer. ABCG2 
has been extensively studied in acute myelogenous leukemia (AML). About 30% of all 
AML patients have high levels of ABCG2 [246]. Although several studies have looked at 
correlation between ABCG2 and clinical outcome, there have been conflicting reports. 
One study found no correlation between expression levels of ABCG2 and clinical 
outcome in 40 newly diagnosed patients [247].  However, Suvannasankha et al. 
demonstrated that ABCG2 mRNA expression correlated very poorly with ABCG2 protein 
expression [248]. In the above study on correlation, the researchers did note that only a 
small percentage of cells had a functional level of ABCG2. This may mean treatment 
selects for cells with high expression at the protein level. It was found in a paired study, 
taking AML cell samples pre-treatment and at the time of relapse, that ABCG2 was 
higher in relapsed samples [249]. Pretreatment mRNA levels of ABCG2 showed that 
fewer patients with high expression obtained complete remission compared to patients 
with low expression, and they also had lower disease-free survival times [250].  CML 
patients have also shown a population of premature CML expressing high levels of 
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ABCG2 [251]. Expression was detected in 25% of cells in 5 out of 7 patients [251]. While 
the importance of ABCG2 in clinical outcome is still to be determined, one recent study 
found that patients with high expression of ABCG2 had a decrease in overall treatment- 
free remission times after discontinuation of tyrosine kinase inhibitors [252].  
Furthermore, ABCG2 has been observed in solid tumors. In a study of 150 
untreated tumors comprising 21 different tumor types, immunohistochemical staining 
for ABCG2 frequently was positive [253]. This study revealed that ABCG2 expression was 
most frequently observed in adenocarcinomas of the digestive tract, endometrium, 
lung, and melanoma. Later studies have found that ABCG2 expression is a prognostic 
factor for both drug response and progression free survival in small-cell lung cancer 
[254]. It was also associated with shorter survival in patients with non-small-cell lung 
cancer [255]. Targeting ABCG2 has been considered in the treatment of cancers with 
overexpression of this protein. The first identified inhibitor of ABCG2 was fumitremorgin 
C (FTC). FTC was identified as a chemo-sensitizing agent to mitoxantrone before it was 
shown to specifically bind to ABCG2 [256, 257]. Unfortunately, FTC cannot be used in 
the clinic due to neurotoxicity. Many other inhibitors of ABCG2 have been discovered or 
developed since identification of FTC. Some of these include Ko143 [258], PZ-39 [259], 
and tryprostatin A [260]. While there have been numerous reports of ABCG2 inhibitors, 
few have made it into clinical trials and none have been approved for clinical use. 
Identifying substrates of ABCG2 will help to predict response to treatment with certain 
drugs and knowing ABCG2 status can help to inform on which treatment options will not 
be effective
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CHAPTER 2: MATERIALS AND METHODS 
Section 2.A: Reagents 
Table 1: Buffers 
Buffer Formula  
PBS 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4 
TBS 50 mM Tris, 150mM NaCl, pH 7.4 
PBST 
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, 0.05% 
Tween 
TBST 50 mM Tris, 150mM NaCl, pH 7.4, 0.05% Tween 
TNN 
50mM Tris-HCl (pH7.4), 150 mM NaCl, 20 mM EDTA (pH 8.0), 50 mM 
NaF, 0.5% NP-40, 1mM Na3VO4, before each use add 20 µl 10% SDS, 10 
µl 0.2M PMSF, and 140 µl 1M DTT to every 2 ml buffer. 
2X SDS 
loading  
100 mM Tris-Cl, pH 6.8, 4% (w/v) SDS, 0.2% (w/v) bromophenol blue, 
20% (v/v) glycerol, 200 mM 𝝱-mercaptoethanol 
 
Table 2: Reagent list  
Reagents Company Cat # 
1-Kb Quick load ladder New England Biolabs N0552G 
2-Mercaptoethanol Sigma M3148 
5-Hydroxy Lansoprazole Potassium Salt 
Toronto Research 
Chemicals H943711 
5-Hydroxy Lansoprazole Sulfide 
Toronto Research 
Chemicals 131926-96-0 
5-mL polystyrene round-bottom tube 
with cell-strainer Cap Fisher 352235 
Acetyl-CoA Sigma A2181 
Acrylamide/bis- 37.5:1 RPI 7732-18-5 
Adenine Sigma 73-24-5 
Ammonium Pursulfate (APS) Fisher 7727-54-0 
Apoptosis Detection Kit Calbiochem PF032-1EA 
Bovine Serum Albumin (BSA) Fisher BP1600-100 
carbxy-H2DCFDA Invitrogen C400 
CC-115 Selleckchem S7891 
CellRox Green Fisher C10444 
Crystal Violet Fisher C581-25 
DMEM Fisher 10-013-CV 
DMEM:F12 (1:1) Fisher 11330-032 
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Donkey Serum Sigma D9663 
Doxorubicin Sigma D1515 
Dual-Luciferase Reporter Assay  Promega E1960 
ECL Western Blot detection reagent GE Healthcare RPN2106 
EGF Fisher PHG0313 
FBS Fisher A3160601 
Free Fatty Acid Quantification Kit Abcam ab65341 
FTC Millipore 344847 
G418 TEKnova G5005 
Gel Loading Dye (6X) New England Biolabs B7025S 
High capacity cDNA  Fisher 4368814 
Hoescht Fisher 62249 
Horse Serum Fisher 26050088 
Hydrocortisone Sigma 50-23-7 
Instant Milk  Walmart   
Insulin Santa Cruz sc-360248 
Lansoprazole 
Toronto Research 
Chemicals L175000 
Lansoprazole Sulfide 
Toronto Research 
Chemicals L175020 
Lansoprazole Sulfone 
Toronto Research 
Chemicals L175026 
Lipofectamine 3000 Invitrogen L3000-015 
Malonyl-CoA Sigma M4263 
MEM Fisher 10-010-CV 
Menadione Sigma M5625 
Methylene Blue Hydrate Sigma M4159 
Mitoxantrone Abcam ab145668 
MnTBAP Fisher 55266-18-7 
NAC Sigma A7250 
NADPH Roche 10107824001 
Nu7441 Selleckchem S2638 
Paraformaldehyde Fisher  4042 
Pencillin/Streptomycin Fisher 17-602E 
Plasmid Prep Invitrogen K210014 
Prestained Protein Ladder Fisher 26616 
Protein Assay Kit Thermo Fisher 23200 
PureLink mRNA extraction kit Invitrogen 12183018A 
Puromycin  Sigma 58-58-2 
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PVDF Fisher 162-0184 
Reporter Lysis 5X buffer Promega E397A 
ROCK inhibitor Chemdea CD0141 
TEMED Fisher 110-18-9 
Thiazolyl Blue Tetrazolium Bromide  Sigma M5655 
Toluene Mounting Media Fisher SP15-100 
Triton X 100 Sigma T8787 
Trypsin Fisher 17-161E 
Tween20 Fisher BP337 
 
Section 2.B: Cell Culture 
Cell lines were authenticated using short tandem repeat on August 3, 2016. All 
cells were maintained at 37°C with 5% CO2. MCF7, M3K, MDA-MB-231, MDA-MB-468, 
HEK293, BC19, MCF7/Vec, MCF7/FASN, M3K/Scr, M3K/shFASN, HEK293/Vec, 
HEK293/ABCG2, MCF7/ABCG2, and HEK293/MRP1 cells were all grown in DMEM 
(Corning, Manassas, VA) media supplemented with 10% FBS (Life Technologies, Grand 
Island, NY). HCC1937 cells were cultured in RPMI (Corning, Manassas, VA) supplemented 
with 10% FBS. MDA-MB-436, MDA-MB-436/Vec and MDA-MB-436/FASN were cultured 
in MEM (Corning, Manassas, VA) supplemented with 10% FBS. KTB cells were cultured in 
a mix of 3:1 F12 (Gibco, Carlsbad, CA) and DMEM low glucose (Corning, Manassas, VA) 
with 5% FBS, 0.4 µl/ml hydrocortisone (Arcos, New Jersey), 1% penicilin/streptomycin 
(Lonza, Walkersville, MD), 5 µg/ml Insulin (Santa Cruz), 10 ng/ml EGF (Gibco, Carlsbad, 
CA), and at the time of culture add 2.4 µg/ml adenine (Sigma, Saint Louis, MO) and 5 µM 
ROCK inhibitor (Chemdea, Ridgewood, NJ). Additionally, M3K and BC19 cells were grown 
in 5 µM and 0.1 µM Doxorubicin (Sigma, Saint Louis, MO) respectively and MCF7/Vec, 
MCF7/FASN, M3K/Scr, MCF7/ABCG2, M3K/shFASN, HEK293/Vec, HEK294/ABCG2, 
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HEK293/MRP1, MDA-MB-436/Vec, MDA-MB-436/FASN, were all maintained in 600 
µg/ml G418 (TEKnova, Hollister, CA).  
M3K cells were a gift from Dr. Susan Bates, Bates also referred to as 
MCF7/AdrVp3000, and were made by incubating parental MCF7 cells in increasing 
concentrations of doxorubicin over an extended period, resulting in doxorubicin 
resistant cell line M3K [261]. BC19 cells were also a gift from Dr. Julie Horton and were 
created by transfection with pBCAdr as described previously [262]. Cell line culture 
information and catalog numbers are provided in Table 2 and 3. Cell line origins and 
plasmid information is provided in Tables 4 and 5. 
Table 3: Cell lines and Media 
Cell Line Media  FBS/HS Other 
MCF7 
DMEM 10% FBS 
  
M3K 5 µM Doxorubicin 
MDA-MB-231   
MDA-MB-468   
HEK293   
BC19 0.1 µM Doxorubicin 
MCF7/Vec 
600 µg/ml G418 
MCF7/FASN 
M3K/Scr 
M3K/shFASN 
HEK293/Vec (Venus)  
HEK293/ABCG2 
MCF7/ABCG2 
HEK293/Vec 
HEK293/MRP1 
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HCC1937 RPMI 10% FBS   
MDA-MB-436 
MEM 10% FBS 
  
MDA-MB-436/Vec 
600 µg/ml G418 
MDA-MB-436/FASN 
MCF10A  DMEM F12 5% HS 
Insulin (10 µg/ml), EGF 
(20 ng/ml), 
Hydrocortisone (500 
ng/ml), Cholera Toxin 
(100 ng/ml) 
KTB22 F12 (Gibco 
11765-054) 
- 375mL, 
DMEM (low 
glucose 
Gibco 
12320-32) - 
125ml,  
5% FBS 
Hydrocortisone (0.4 
µl/ml), 
Penicilin/streptomycin (5 
ml in 500 ml bottle), 
Insulin (5 µg/ml), EGF (10 
ng/ml), add at time of 
culture; Adenine (2.4 
µg/ml), ROCK inhibitor (5 
µM) 
KTB34 
KTB39 
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Table 4: Breast Cancer subtype for each cell line and identification of plasmids used for 
stable transfection. 
Cell Line Origin 
MCF7 Luminal A breast cancer 
M3K Derived from MCF7 
HCC1937 TNBC  
MDA-MB-231 TNBC  
MDA-MB-468 TNBC  
MDA-MB-436 TNBC  
HEK293 Human embryonic kidney cells 
BC19 MCF7 transfected with pBCAdr 
MCF7/Vec 
MCF7 transfected with 
pcDNA3.1 (+)  
MCF7/FASN 
MCF7 transfected with 
pcDNA3.1 (+) containing FASN 
MDA-MB-436/Vec 
MDA-MB-436 transfected with 
pcDNA3.1 (+) 
MDA-MB-436/FASN 
MDA-MB-436 transfected with 
pcDNA3.1 (+) containing FASN 
M3K/Scr 
M3K transfected with 
Scrambled control 
M3K/shFASN 
M3K transfected with shRNA 
targeting FASN 
HEK293/Vec  
HEK293 transfected with 
pcDNA3.1 (+) 
HEK293/MRP1 
HEK293 transfected with 
pcDNA3.1 (+) containing MRP1 
HEK293/Vec (Venus) 
HEK293 transfected with 
pCDH-Ne0-Venus/Dest 
HEK293/ABCG2 
HEK293 transfected with 
pCDH-Ne0-Venus/Dest 
containing ABCG2 
MCF7/ABCG2 
MCF7 transfected with 
pcDNA3.1 (+) containing 
ABCG2 MYC tagged 
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Table 5: Identification of Non-cancerous cell lines utilized and their origin. These cells 
were graciously given by Dr. Nakshatri and have just recently been characterized by his 
lab [263]. 
Cell Line Origin 
MCF10A  Non-cancerous Breast Cell line 
KTB22 
Non-cancerous Breast Cell line 
obtained from a Hispanic 
patient   
KTB34 
Non-cancerous Breast Cell line 
obtained from a  
Caucasian patient   
KTB39 
Non-cancerous Breast Cell line 
obtained from an African 
American patient   
 
Section 2.C: Western Blot 
Cells were treated with lansoprazole and its metabolites for the indicated time 
changing media and drug every 24 hours. At the given time points cell pellets were 
collected by centrifugation at 5,000 rpm for 5 min. Supernatant was aspirated and 
pellets were washed with PBS (refer to Table 1) 3 times followed by centrifugation at 
5,000 rpm for 5 min and aspiration of supernatant each time. Cells were then 
resuspended in TNN buffer (refer to Table 1) and vortexed for 1 min every 10 mins for 
30 min. The cell lysates were sonicated for 10 seconds at 40% 4 times with a 1 min rest 
on ice between sonication before centrifugation at 13,000 rpm for 20 min. Supernatants 
were transferred to a new microcentrifuge tube leaving behind cellular debris. Protein 
concentrations were then measured using the biorad protein assay dye (Pierce 
Biotechnology, Rockford, IL) to ensure equal loading. Samples are mixed with 2X SDS 
loading buffer (refer to Table 1) and boiled at 90°C for 5 min, before being separated by 
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8-15% SDS-PAGE gel, depending on the size of the protein, transferred overnight to a 
PVDF membrane (Biorad, Rockford, IL), and western blots were performed the following 
morning. Membranes were first blocked in 5% milk in TBST (refer to Table 1) buffer for 2 
hours and then probed with the primary antibodies listed in Table 6 for 2 hours, or 
overnight for phosphorylated probes. Primary antibodies were diluted in 5% milk in 
TBST buffer and 5% BSA in TBST for phosphorylated proteins. Membranes were then 
washed 3 times for 15 min each time with TBST or PBST (refer to Table 1) and then 
placed in secondary, which was diluted in 5% milk in TBST. Membranes were washed 3 
times for 15 min each time with TBST. Blots were visualized using ECL western blot 
detection reagent (Biorad, Chicago, IL). To test CC-115 inhibition of mTOR and its 
downstream targets, cells were treated for 2 hours with the indicated concentration of 
drug. After 2 hours cell pellets were collected, lysed, and protein concentrations were 
determined as described above. After visualization band density was measured by using 
imageJ software. 
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Table 6: Antibodies – list of Antibodies used in all studies with catalog number 
Antibody Company  Catalog # Dilution 
ABCG2 Millipore MAB4146 1:1000 
Actin Sigma JLA-20 1:2000 
AKT Cell Signaling 9272 1:1000 
ALEXA FLUOR 647 Secondary abcam ab150107 1:200 
Anti-Mouse Secondary Sigma A2554 1:3000 
Anti-phospho-histone H2A.X Millipore 05-636 1:1000 
Anti-Rabbit Secondary Sigma A0545 1:3000 
Anti-Rat Secondary  Sigma A9037 1:2000 
Caspase 3 Cell Signaling 9662 1:1000 
Cleaved Caspase 3 Cell Signaling 9661 1:200 
Cleaved PARP Cell Signaling 9451 1:500 
DNA-PKcs  Calbiochem PC127 1:500 
Fatty acid synthase 
BD Transduction 
Laboratories 610963 1:1000 
MRP1 abcam ab3368 1:1000 
mTOR Cell Signaling 2983 1:500 
P-Glycoprotein Antibody (C219) Invitrogen 
MA1-
26528 1:200 
PARP Cell Signaling 9532 1:1000 
Phospho-AKT (S473) Cell Signaling 4051 1:500 
Phospho-p70 S6 Kinase 
(Thr389) Cell Signaling 9234 1:500 
Phospho-S6 Cell Signaling 2215 1:1000 
S6 Cell Signaling 2317 1:200 
S6K Cell Signaling 2708 1:1000 
 
Section 2.D: RT-PCR 
To set up for RT-PCR cells were plated in a 6 well dish at a concentration of MDA-
MB-231 – 1 X 105 and MDA-MB-468 – 2.5 X 105. Cells were treated every 12 hours for 72 
hours with drug. After 72 hours, cells were collected and mRNA was extracted following 
the protocol outlined in the PureLink RNA Mini Kit (Invitrogen, Carlsbad, CA). Following 
mRNA extraction cDNA was produced using the high capacity cDNA kit (Applied 
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Biosystems, Waltham, MA). The thermocycler was set for, stage 1: 25°C – 10 min, stage 
2: 37°C – 120 min, stage 3: 85°C – 5 min, stage 4: 4°C – hold. The cDNA was then used in 
the RTPCR with PARP and GAPDH primers. The primer sequence is listed in Table 7. 
Table 7: RTPCR Primers 
Primer Orientation Sequence 
GAPDH 
Forward 5'-TGCACCACCAACTGCTTAGC-3' 
Reverse 5'-GGCATGGACTGTGGTCATGAG-3' 
PARP 
Forward 5ʹ-CCCAGGGTCTTCGGATAG-3ʹ 
Reverse 5ʹ-AGCGTGCTTCAGTTCATACA-3ʹ 
 
Section 2.E: Proliferation and Survival Assays 
2.E.1 Methylene Blue  
Methylene blue proliferation assay was derived from the protocol described by 
Oliver et al. [264]. Cell lines were plated in 96 well plate in 100 µl media at 500 cells/well 
to 4000 cells/well, depending on the cell line. After 24 hours, cells were treated with 
increasing concentration of drug using DMSO (0.5%) as the control treatment. Drug was 
added in 100 µl of media to each well. Cells were placed in 37°C incubator and allowed 
to grow for 72 hours in the presence of drug. At 72 hours, media was removed by 
aspiration and cells were fixed with 100 µl of methanol for 30 min. Cells were then 
stained with 1% (w/v) methylene blue in 10 mM borate buffer, pH 8.5, for 30 minutes. 
Excess dye was removed by aspiration and plates were then washed 3 times with 
ddH2O. Dye was then released from cells by adding 100 µl of a 1:1 mixture of 100% 
ethanol and 0.1 M HCl. The plate can then be read in a 96 well plate reader at 650 nm. 
The OD correlates to the number of cells in each well. Methylene blue is a basic dye that 
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has a positive charge at pH 8.5. When cells are treated with methylene blue at pH 8.5 its 
binds to negatively charged moieties within the cells including proteins and DNA. After 
washing, the dye is released from cells by lowering the pH, causing protonation of acid 
groups and release of methylene blue into the solution, allowing for OD readings. 
2.E.2 MTT 
Cell lines were plated in 96 well plate in 100 µl media at 500 cells/well to 4000 
cells/well, depending on the cell. After 24 hours, cells are treated with increasing 
concentration of drug, using DMSO (0.5%) as the control treatment. Drug was added in 
100 µl of media to each well in triplicate. Cells were placed in 37°C incubator and 
allowed to grow for 72 hours in the presence of drug. At 72 hours, 20 µl of MTT dye (5 
mg/ml in PBS) was added to each well. Cells were incubated at 37°C for 4 hours. After 
incubations, plates were centrifuged at 2,000 rpm for 10 min, and the supernatant was 
carefully aspirated. Finally, 100 µl of DMSO was added to each well to solubilize the dye, 
and absorbance was read at 570 nm, using 630 nm for background. MTT is a measure of 
cell viability by measuring the metabolic activity. When the MTT dye, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, is taken up by metabolically 
active cells, it is converted to formazan, (E,Z)-5-(4,5-dimethylthiazol-2-yl)-1,3-
diphenylformazn. MTT is yellow in color, and, after being reduced it becomes purple. 
The Absorbance at 570 nm is a reflection of the metabolically active cells. 
2.E.4 Apoptosis Assay 
Cells were plated in a 6-well dish at a concentration of: MDA-MB-231 – 1 X 105 
and MDA-MB-468 – 2.5 X 105. After plating cells were placed in the incubator overnight 
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at 37°C. Then cells were treated with the given concentration of drug every 24 hours for 
72 hours in the case of MDA-MB-231 cells and every 12 hours for MDA-MB-468. In the 
presence of N-acetyl-L-cysteine (NAC) (Sigma, Saint Louis, MO) the media pH had to be 
corrected by adding NaOH. After 72 hour treatment cells were collected and stained for 
Annexin V-FITC and propidium iodide, following manufacturers protocol (Calbiochem, 
Temecula, CA), and then analyzed by FACs. After induction of apoptosis there is a rapid 
change in phospholipids causing the exposure of phosphatidylserine on the cell surface 
which will readily bind Annexin V-FITC. Propidium iodide stain can only enter cells when 
there is a disruption of cellular membranes which would indicate late apoptotic or 
necrotic cells. These dyes together were used to determine number of cells in apoptosis 
following treatment. Briefly, cells were collected and washed with PBS two times. Then 
5 X 105 cells, in 500 µl binding buffer (provided in the kit), were stained with Annexin V-
FITC for 15 min at room temperature. Cells were centrifuged at 1000 X g for 5 min and 
the supernatant was removed. Cells were resuspended in 500 µl binding buffer and 
propidium iodide. Samples were run through 5-mL polystyrene round-bottom tube with 
cell-strainer Cap and run on BD LSR II analyzer (excitation 488 nm FITC- emission 518nm 
and propidium iodide 620 nm). H2O2 was used at a concentration of 100 µM for 30 min 
as a positive control for apoptosis. 
2.E.5 Cell Cycle Analysis 
Cells were plated in 10 cm dish at a concentration of 4 X 105 for MDA-MB-231 
cells and 6 X 105 for MDA-MB-468 cells and incubated overnight at 37°C. Cells were then 
treated with the given concentration of drug for 72 hours. Cells were harvested with 
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trypsin and washed 3 times with PBS. 70% ice cold ethanol was used to fix cells for 30 
min, making sure to separate cellular clumps. Cells were then washed 2 times with PBS 
and treated with 500 µl of 20 µg/ml RNAse in PBS for 30 min at 37°C. Cells were pelleted 
and supernatant was aspirated. Pellets were resuspended in 500 µl of 50 µg/ml 
propidium iodide in PBS and incubated at room temperature for 30 min. Cells were 
filtered through 5 mL polystyrene round-bottom tube with cell-strainer cap for FACs 
analysis. 
 
Section 2.F: Drug Accumulation Assay 
Cells were trypsinized and pelleted by centrifugation. They were then washed 
twice with warm PBS. Cells were then resuspended in 1 ml of warm PBS. ABCG2 
inhibitor was added at given concentrations and cells were incubated for 15 min at 37°C. 
Then, 10 mM CC-115 or DMSO control was added to the suspended cells, and cells were 
incubated at 37°C for 30 min, shaking every 10 min. After treatment cells were pelleted 
by centrifugation and washed with PBS 1 time. Cells were resuspended in 500 µl PBS 
and filtered through 5 mL polystyrene round-bottom tube with cell-strainer cap. 
Accumulation was measured by FACs with an excitation at 405 nm and emission 421 
nm. 
 
Section 2.G: Confocal Microscopy  
For confocal microscopy cells were grown on a sterilized coverslip to about 80% 
confluency. To do this first the cover slips were first autoclaved, and one coverslip was 
 51 
placed in each well of a 6-well plate. Cells were plated at a concentration of 2 X 105 for 
MDA-MB-231 and 2.5 X 105 for MDA-MB-468. Cell concentrations will vary based on the 
growth rate of cells. After 24 hours, media was carefully aspirated and cells were 
treated with the appropriate amount of drug. Cells will be treated every 24 hours for 72 
hours. At 72 hours media was aspirated and cover slips were washed with PBS twice for 
5 min. Slides were fixed with 4% paraformaldehyde for 15 min at room temperature and 
washed 3 times with PBS for 5 min each time. Then slides were blocked and 
permeabilized in PBS with 5% normal donkey serum (Sigma, Saint Louis, MO), and 0.3% 
triton X 100 (Sigma, Saint Louis, MO) for 60 min. Permeabilization buffer was removed 
and slides were placed in primary antibody overnight at 4°C (PBS, 1% BSA, 0.3% Triton X 
100). Slides were washed with PBS 3 times 5 min each time. Secondary antibody was 
diluted 1:200 in PBS, 1% BSA, and 0.3% Triton X 100 and slides incubated for 60 min at 
room temperature in the dark. (Negative controls should also be incubated in secondary 
antibody) Secondary antibody was removed and Hoescht (Pierce Biotechnology, 
Rockford, IL) was diluted in 25 µl in 250 ml PBST. 2 ml of diluted Hoescht was added to 
each well and allowed to sit in the dark for 10 min. Slides were then prepared with 
toluene mounting media (Fisher, Fair Lawn, NJ) and sealed using nail polish. Slides were 
imaged using the Olympus2 FV-1000 MPE inverted confocal imaging system and the 
60X/1.2 W ∞/0.13-0.21/FN26.5 lens. 
2.G.1 Quantification of puncta staining  
γH2AX puncta staining was quantified using the GDSC plugin in on Fiji imageJ 
software. 
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Section 2.H: NHEJ Activity Assay 
To determine NHEJ activity a luciferase and renilla assay system was used as 
previously described [128]. Briefly, pGL3-luc plasmid was first cut by HINDIII, separating 
the promoter sequence from the luciferase gene, creating a linearized plasmid and 
purified using a gel extraction kit (Invitrogen, Carlsbad, CA). Linearization is verified by 
running a 0.8% agarose gel. Upon transfection, this linearized plasmid will be repaired to 
a circular plasmid that expresses luciferase, if NHEJ is active. If it is not active there will 
be no luciferase activity. pRL-TK, renilla plasmid is used as a transfection efficiency 
control and pGL3-Luc is used as 100% control. To test NHEJ after drug exposure cells 
were plated in 24-well plate (MDA-MB-231 – 1 X 104 MDA-MB-468 – 2 X 10 4). Cells 
were treated every 12 hours for 72 hours. After 72 hours cells were co-transfected 
(Lipofectamine 3000, Carlsbad, CA) with pRL-TK (400ng) and pGL3-Luc (400ng) or 
linearized pGL3-Luc (400ng). Cells are incubated at 37°C for 8 hours when they were 
collected for analysis. Briefly, media was aspirated from the 24-well plates and 100 µl of 
1X reporter lysis buffer was added to each well (Promega, Madison, WI). Plates were 
shaken for 10 min and then collected in microcentrifuge tubes. Tubes were then 
subjected to freeze thaw cycles to ensure cell lysis. This was accomplished by using dry 
ice/ethanol bath of 2 min and then 2 min in 37°C water bath. Lysates were centrifuged 
at 13,000 rpm for 2 min and supernatant was transferred to a new tube. Using first 20 µl 
of firefly luciferase substrate (substrate E151A and buffer E195A, Promega, Madison, 
WI) and 5 µl lysate, firefly luciferase was measured. Then 20 µl of Stop & Glo substrate 
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(substrate E640A and buffer E641A, Promega, Madison WI) was added to measure 
Renilla. NHEJ was determined by the following formula. 
(Luciferase/(linearized)/Renilla)(treatment X) ÷ (Luciferase/(circularized)/Renilla)(treatment X) = % NHEJ 
2.H.1 Plasmid Prep 
To obtain the plasmids for NHEJ DH5∝ cells were chemically transformed with 
pRL-TK and pGL3 plasmid. After growth a single colony was picked and placed in 500 ml 
LB media and allowed to grow overnight at 37°C with agitation. Cells were then 
collected by centrifugation at 4,000 g for 10 min and supernatant was removed. 
Following the PureLink HiPure Plasmid Filter DNA Purification Kit protocol (Invitrogen, 
Carlsbad, CA), plasmids were extracted from cell lysates. 
 
Section 2.I: FASN Activity Assays 
2.I.1 Free Fatty Acid Quantification Assay  
Free fatty acids were quantified using the protocol provided by the Abcam free 
fatty acid quantification kit (Abcam, Cambridge, MA). Briefly, acyl CoA synthetase is 
used in acylation of coenzyme A. In this way free fatty acids are converted to CoA 
derivatives. Then the acyl-CoA is oxidized by an acyl CoA oxidase. Upon oxidation H2O2 is 
produced, which reacts with the colorimetric probe and can be easily quantified by 
microplate reader at λ=570 nm. To start this assay cells are plated in 150 mm dish, 2 
dishes per condition, and treated every 24 hours with drug for 72 hours. At 72 hours 
cells are collected via trypsinization, counted, and washed with PBS. Cells are 
resuspended in 200 µl chloroform/1% triton X-100 and homogenized using a micro-
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homogenizer. Homogenate was placed on ice for 30 min and then centrifuged at 13,000 
rpm for 10 min. The lower organic phase was collected into a new microcentrifuge tube 
and allowed to air dry in a chemical hood at 50°C to remove chloroform (about 1 hour). 
To ensure total removal of chloroform samples were vacuum dried for 30 min. Samples 
were then resuspended in fatty acid assay buffer (provided by the kit), heated at 85°C 
and vigorously vortexed for 5 min. Before use in the assay samples were quickly 
centrifuged at 7,000 rpm to remove any debris. 
 
Section 2.J: Measurement of Reactive Oxygen Species 
To measure reactive oxygen species cells were plated in a 96 well black plate 
with clear bottoms. MDA-MB-231 cells were plated at 20,000 cells per well and MDA-
MB-468 cells were plated at 25,000 cells per well to obtain 90% confluence after 
incubation overnight at 37°C. Cells were then treated with indicated concentrations of 
drug for indicated time period in 100 µl Opti-MEM at 37°C. Menadione at a 
concentration of 100 µM was used as a positive control, treated for 2 hours. NAC and 
MnTBAP were used as reactive oxygen scavengers. After treatment 100 µl of CellROX 
green (Molecular Probes, Eugene, OR) is added for a final concentration of 5 µM, while 
being protected from light. The plate is then placed back in the incubator for 30 min at 
37°C. Continue to protect the plate from light and after incubation 200 µl of 8% PFA is 
added to each well to fix cells for 15 mins. The plate is gently poured into a waste 
container tapped onto a stack of paper towel. Wells are carefully washed with 200 µl of 
PBS 3 times and each time the PBS is gently poured off and the plate is tapped on a 
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stack of paper towels. The wells are then filled with 100 µl of PBS and are ready to be 
read in the microplate reader. CellROX green begins to brightly fluoresce when it 
becomes oxidized by reactive oxygen species and binds to DNA. Therefore, plates were 
read at excitation of 485 nm and emission 520 nm. 
 
Section 2.K: Statistical Analysis 
Statistical analysis for all experiments was run using Prism Graphpad. Results are 
presented as ± SD unless otherwise indicated. All statistics were run on triplicate 
experiments unless otherwise indicated. Statistics are as follows P<0.05 = *, P<0.01 = **, 
and P<0.001 = ***. Statistical tests used in this thesis were the two-tailed T-test 
comparing two means, ANOVA for comparing a group of mean values, and Two-Way 
ANOVA for comparing cell cycle analysis after treatment.  
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CHAPTER 3: RESULTS 
Section 3.A: 5-Hydoxy Lansoprazole Sulfide 
3.A.1 Lansoprazole and its metabolite 5-Hydroxy Lansoprazole Sulfide have cytotoxic 
effects in TNBC cell lines. 
 Proton pump inhibitors are FDA-approved drugs that have been on the market 
since 1989 [179]. They have been used in the successful treatment of many different 
non-cancerous acid related diseases. With the identification of PPIs as a FASN inhibitor 
[178] and the known role of FASN in cancer, our lab wanted to determine if inclusion of 
PPIs into breast cancer treatment could improve overall patient survival. To look at this 
possibility a retrospective study was performed on just over 6,700 patients diagnosed 
between January 1st, 1995 and February 27th, 2014. 840 of whom started taking a PPI 
during treatment.  These studies to be published by other lab members, (manuscript in 
preparation) used log-ranked statistical analysis to show that breast cancer patients 
who were taking a PPI concurrently with treatment had a significant increase in overall 
survival. This retrospective study included patients with different treatment courses 
including hormone therapy, irradiation, DNA damaging chemotherapeutics, and cell 
cycle inhibitors. When the data was separated by the PPI utilized, it showed that 
lansoprazole, omeprazole, and pantoprazole, in combination with chemotherapy, had 
the highest overall survival. Furthermore, when the data was analyzed based on the 
subtype of breast cancer, TNBC patients that used a PPI during chemotherapy had a 
significant increase in survival over those that did not with a p-value of 0.015.  
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Using this information, the effect of PPI’s on cells in a lab setting was analyzed. 
Data from our lab and others has shown that the different proton pumps have varying 
effects on cancer cells. Both our lab and others [207] have shown that the PPI 
lansoprazole has the greatest observed anti-tumor effects. PPI rabeprazole consistently 
was shown to have the least anti-cancer activity. Analyzing the metabolites of the four 
commonly used PPIs, omeprazole, lansoprazole, pantoprazole, and, rabeprazole, (Figure 
6) it can be seen that omeprazole, lansoprazole, and pantoprazole are all degraded in a 
similar enzymatic fashion, by similar CYP450s, while rabeprazole is mostly degraded 
non-enzymatically. Omeprazole, Lansoprazole, and pantoprazole are degraded by 
CYP3A4 and CYP2C19. This led us to the hypothesis that a metabolite of these drugs may 
have antitumor activity. Based on our preliminary data that PPIs have inhibitory effects 
on FASN, we further hypothesized that a metabolite of lansoprazole also had inhibitory 
effects on FASN. In this thesis it is shown that inhibition of FASN by 5-hydroxy 
lansoprazole sulfide leads to a decrease in PARP and a decrease in the DNA repair 
pathway, NHEJ, causing accumulation of DNA damage and cellular apoptosis. 
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Figure 6: Metabolic Pathways for Proton Pump Inhibitors – The four commonly used 
proton pump inhibitors and how they are degraded in the body. Lansoprazole, 
omeprazole, and pantoprazole are all degraded mainly in an enzymatic fashion by 
CYP450s, while rabeprazole is mostly degraded non-enzymatically. Lansoprazole, 
omeprazole, and pantoprazole metabolism leads to formation of very similar 
metabolites including sulfones, 5-hydroxy, and sulfides. Thickness of the lines indicates 
the major and minor pathways of degradation.  
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Figure 7: Lansoprazole’s Metabolites – Lansoprazole and its metabolites chemical 
structures. Size of arrows indicates the major and minor routes of metabolism by 
CYP3A4 and CYP2C19. 
 
Based on the retrospective study and cell based studies in our lab and others 
[207] indicating lansoprazole had the greatest anti-cancer effect, lansoprazole 
metabolites were used to test their effect on breast cancer cell lines. The parent 
compound and metabolites used in this study are shown in Figure 7. These compounds 
were first tested in MCF7, MDA-MB-231 and MDA-MB-468 cells. MCF7 cells are luminal 
A type breast cancer cells while MDA-MB-231 and MDA-MB-468 are TNBC cell lines. 
Using the methylene blue assay, the IC50 to the parent compound, lansoprazole, and 
each metabolite was determined. As shown in Figure 8A-C, there was a wide variety of 
response to different agents. All three cell lines tested had high IC50 values to the 
metabolite lansoprazole sulfone. This would indicate that this metabolite has very 
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minimal anti-cancer activity or it is also possible that this metabolite is not permeable to 
the cell membrane. Lansoprazole sulfide, while having lower IC50 than lansoprazole 
sulfone, still had an IC50 significantly higher than parent compound lansoprazole. 5-
hydroxy lansoprazole potassium salt did not have a significantly different IC50 as 
compared to parent compound lansoprazole in both TNBC cell lines but was significantly 
higher in MCF7 cells. The last metabolite 5-hydroxy lansoprazole sulfide had no 
significant difference in IC50 value in MCF7 cells but IC50 values were significantly 
decreased in both MDA-MB-231 and MDA-MB-468 TNBC cells (Figure 8D-F) compared 
to parent compound lansoprazole. These observed differences in sensitivity in different 
cell lines could be attributed to differences between luminal A type cancers and TNBC or 
differences in expression levels of CYP enzymes in these particular cells (see discussion). 
The possibility that a metabolite of lansoprazole may be a more effective treatment in 
TNBC has been intriguing. For this reason, the IC50 values to lansoprazole and 5-hydroxy 
lansoprazole sulfide were tested in an additional two TNBC cell lines.  
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Figure 8: Effect of Lansoprazole and its Metabolites on Breast Cancer Cell lines – IC50 
values for lansoprazole and its metabolites in MCF7 (A), MDA-MB-231 (B), and MDA-
MB-468 (C) cell lines. Survival curves for lansoprazole (red •) and 5-hydroxy lansoprazole 
sulfide (Blue ■) in MCF7 (D), MDA-MB-231 (E), and MDA-MB-468 (F). (all n=3) Statistical 
analysis ANOVA P<0.05 = *, P<0.01 = **, and P<0.001 = *** 
 
The additional breast cancer cell lines tested were MDA-MB-436 and HCC1937. 
Figure 9A, D-E shows that all four TNBC cell lines are more sensitive to treatment with 5-
hydroxy lansoprazole sulfide than parent compound lansoprazole. Interestingly, there 
was no significant difference in treatment with lansoprazole or 5-hydroxy lansoprazole 
sulfide in non-cancerous breast epithelial cell lines (Figure 9B, F-H). The non-cancerous 
cell lines KTB22, KTB34, and KTB39 were derived from Hispanic, Caucasian, and African 
American samples, respectively, and were a gift from Dr. Nakshatri [263]. They were 
immortalized by transfection with hTERT. Figure 9C shows the average IC50 values for all 
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TNBC and non-cancerous cell lines tested. The IC50 values for TNBC cell lines treated 
with 5-hydroxy lansoprazole sulfide is significantly lower than all other treatment 
groups. This indicates an in vitro therapeutic window. 
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Figure 9: Lansoprazole and 5-Hydroxy Lansoprazole Sulfides effect on TNBC cell and 
non-cancerous breast cell lines - A) IC50 values to lansoprazole and 5-hydroxy 
lansoprazole sulfide (5HLS) in luminal A breast cancer cell line MCF7 and TNBC cell lines 
MDA-MB-231, MDA-MB-468, MDA-MB-436, and HCC1937. B) Response to lansoprazole 
and 5-Hydroxy lansoprazole sulfide in non-cancerous breast cell lines KTB22, KTB34, and 
KTB39. C) Average IC50 values for TNBC cell lines tested as well as non-cancerous cell 
lines. Survival curves for lansoprazole (red •) and 5-hydroxy lansoprazole sulfide (Blue ■) 
in MDA-MB-436 (D), HCC1937 (E), and the KTB22 (F), KTB34 (G), and KTB39 (H) cell lines. 
(all n=3) Statistical analysis using a T-test comparing IC50 of lansoprazole and 5HLS in 
each cell line (A) and ANOVA comparing all groups (C) was used. P<0.05 = *, P<0.01 = **, 
and P<0.001 = *** 
 
 64 
3.A.2 5-Hydroxy Lansoprazole Sulfide causes apoptosis 
 To determine the effect 5-hydroxy lansoprazole sulfide has on TNBC cells, cell 
cycle analysis and apoptosis assays were performed. As shown in Figure 10A-D, while 
there are apoptotic/necrotic cells after treatment with 5-hydroxy lansoprazole sulfide, 
the distribution between phases of the cell cycle was not affected as indicated by a two-
way ANOVA. 
 
Figure 10: Treatment of TNBC cell line MDA-MB-231 with lansoprazole of 5-hydroxy 
lansoprazole sulfide does not affect cell cycle – MDA-MB-231 cells were treated with 
10 µM drug for 72 hours and cell cycle analysis was performed using flow cytometry. 
(n=3) 
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Due to the lack of cell cycle arrest in MDA-MB-231 cells, the amount of apoptosis 
was measured using annexin and propidium iodide staining. Using the kit provided by 
calbiochem (#PF032-1EA), apoptosis was checked at 48 and 72 hours. Figure 11 shows 
the scatterplots obtained using this kit and detecting PI and annexin staining. While 
treating the MDA-MB-231 cells with 10 µM concentration of drug for 48 hours did not 
induce apoptosis (Figure 11A-C), treatment with 10 µM concentration for 72 hours 
induced apoptosis in 5-hydroxy lansoprazole sulfide treated cells (Figure 11 D-F). 
Quantification of apoptosis in MDA-MB-231 cells after 72 hours treatment is shown in 
Figure 11G. MDA-MB-468 cells also showed apoptosis at 72 hours when treated with a 
20 µM concentration (Figure 12A-D). Additionally, due to the high staining of PI, which 
could indicate necrotic cells rather than apoptotic, and the long treatment, apoptosis 
was confirmed in MDA-MB-231 cells by using cleaved PARP and cleaved caspase 3 
antibodies to show that apoptotic pathways are active in these cells. Figure 13A-E shows 
that with an increase in concentration of 5-hydroxy lansoprazole sulfide there is an 
increase in both cleaved PARP and cleaved caspase 3. Cleaved PARP molecular weight is 
89 kDa and cleaved caspase 3 has two cleavage products one at 17 kDa and one at 19 
kDa. MDA-MB-468 cells also had an increase in cleaved PARP and cleaved caspase 3 as 
shown in Figure 14. However, in MDA-MB-468 cells higher concentrations of drug were 
needed to see cleaved PARP and cleaved caspase 3. Additionally, there does not seem 
to be a significant difference in caspase 3 cleavage or PARP cleavage between 
lansoprazole and 5-hydroxy lansoprazole sulfide treated MDA-MB-468 cells. The fact 
that caspase cleavage in 5-hydroxy lansoprazole treated cells is not greater than 
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lansoprazole treated, and that 5-hydroxy lansoprazole sulfide leads to a greater increase 
in apoptotic/necrotic cells using annexin and propidium iodide staining, this could 
indicate that cells are potentially dying through another mechanism such as necroptosis 
which could explain why caspase 3 cleavage is not as pronounced (See Discussion). 
Further repeats should be performed to confirm these western blots and perform 
quantification. 
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Figure 11: Treatment with 5-hydroxy lansoprazole sulfide induces apoptosis in MDA-
MB-231 cells - MDA-MB-231 cells were treated for 48 hours with DMSO (A), 10 µM 
lansoprazole (B), and 10 µM 5-hydroxy lansoprazole sulfide (C). MDA-MB-231 cells were 
treated 72 hours with DMSO (D), 10 µM lansoprazole (E), and 10 µM 5-hydroxy 
lansoprazole sulfide (F). Quantification of apoptotic cells is given in G at 72 hour 
treatment and an ANOVA comparing all three groups was used for statistical analysis. 
P<0.05 = *, P<0.01 = **, and P<0.001 = ***. (n=3) 
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Figure 12: Treatment with 5-hydroxy lansoprazole sulfide induces apoptosis in MDA-
MB-468 - MDA-MB-468 cells were treated for 72 hours with DMSO (A), 20 µM 
lansoprazole (B), and 20 µM 5-hydroxy lansoprazole sulfide (C). Quantification of 
apoptotic cells is given in D and an ANOVA comparing all three groups was used for 
statistical analysis. P<0.05 = *, P<0.01 = **, and P<0.001 = ***. (n=3) 
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Figure 13: Treatment with MDA-MB-231 induces cleavage of PARP and caspase 3 - 
MDA-MB-231 cells treated with increasing concentrations of lansoprazole and 5-
hydroxy lansoprazole sulfide were analyzed to determine the amount of cleaved PARP 
and cleaved caspase 3 (A). Quantification of cleaved PARP/Actin (B), cleaved PARP/PARP 
(C), and the two cleavage products of caspase 3: 17 kDa (D) and 19 kDA (E). (n=3) 
ANOVA comparing all groups was used for statistical analysis. P<0.05 = *, P<0.01 = **, 
and P<0.001 = *** 
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Figure 14: Treatment of MDA-MB-468 with lansoprazole and 5-hydroxy lansoprazole 
sulfide induces cleaved PARP and cleaved caspase 3 – Cleaved PARP and Cleaved 
Caspase 3 in MDA-MB-468 cells. (n=2) 
 
3.A.3 Treatment with 5-Hydroxy Lansoprazole Sulfide increases DNA double strand 
breaks 
 FASN expression has been shown to be associated with resistance to DNA 
damaging agents [128] by increasing DNA repair pathway NHEJ. When FASN was 
overexpressed or knocked down, NHEJ repair increased and decreased, respectively, 
affecting resistance to DNA damaging agents. To test the possibility that 5-hydroxy 
lansoprazole sulfide is inhibiting FASN which would thereby increase DNA damage, the 
amount of γH2AX was determined by western blot analysis and puncta staining using 
confocal imaging. γH2AX can be used as an indicator of DNA DSBs [265, 266]. H2AX is a 
histone that becomes phosphorylated by ATM or DNA-PKcs in response to DNA DSBs 
[267]. Phosphorylation of H2AX leads to the recruitment of repair proteins and will 
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persist until the damage is repaired at which point the phosphate is removed by a three-
protein complex known as HTP-C [268]. Treatment with lansoprazole and 5-hydroxy 
lansoprazole sulfide increases γH2AX staining with increasing concentrations in both 
MDA-MB-231 (Figure 15A and C) and MDA-MB-468 (Figure 15D and F) cells. At the same 
concentration of drug, 5-hydroxy lansoprazole sulfide produces significantly more DNA 
DSBs than lansoprazole. We also observed a significant decrease in PARP expression in 
both MDA-MB-231 (Figure 15B) and MDA-MB-468 (Figure 15E) cells which will be 
discussed later. To confirm γH2AX puncta staining is within the nucleus, confocal 
imaging was used. As shown in Figure 16A-C, 5-hydroxy lansoprazole sulfide significantly 
increased γH2AX in treated cells as compared to lansoprazole. Quantification of the 
number of γH2AX foci in the nucleus (Figure 16C) shows that at the same concentration 
5-hydroxy lansoprazole sulfide creates significantly more foci/nucleus than parent 
compound lansoprazole. Interestingly, when treating the non-cancerous cell lines 
KTB22, KTB34, and KTB39 neither lansoprazole nor 5-hydroxy lansoprazole sulfide 
produced γH2AX staining at IC50 values (Figure 17). While it is not clear why non-
cancerous cells are not affected in the same way this could be due to differences in 
cellular metabolism, differences in cellular growth rate, or potentially that 
FASN/PARP/NHEJ axis may only apply to cancer cells as FASN is not required for benign 
cell survival. Further study is required to determine the differences. 
 72 
 
Figure 15: 5-hydroxy lansoprazole sulfide reduces PARP expression and increases 
γH2AX - A) MDA-MB-231 cells treated with increasing concentrations of parent 
compound, lansoprazole, and metabolite 5-hydroxy lansoprazole sulfide with 
quantification for PARP expression (B) and γH2AX (C). D) MDA-MB-468 cells treated with 
increasing concentrations of lansoprazole and 5-hydroxy lansoprazole sulfide with 
quantification for PARP expression (E) and γH2AX (F). (n=3) ANOVA comparing all groups 
was used for statistical analysis. P<0.05 = *, P<0.01 = **, and P<0.001 = *** FASN was 
also quantified but showed no significant difference in any treatment group. 
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Figure 16: 5-hydroxy lansoprazole sulfide treatments leads to DNA double stand 
breaks as indicated by γH2AX puncta staining - MDA-MB-231 cells treated with 10 µM 
lansoprazole and 5-hydroxy lansoprazole sulfide (A) and (B) MDA-MB-468 cells treated 
with 20 µM lansoprazole and 5-hydroxy lansoprazole sulfide. C) Quantification of 
number of γH2AX foci within the nucleus compared using an ANOVA for statistical 
analysis. (n=3) P<0.05 = *, P<0.01 = **, and P<0.001 = *** 
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Figure 17: Lansoprazole and 5-hydroxy lansoprazole sulfide does not create DNA 
double strand breaks, as indicated by γH2AX, or induce cleavage of PARP in non-
cancerous breast epithelial cells lines – 5-hydroxy lansoprazole sulfide nor parent 
compound lansoprazole causes DNA damage in non-cancerous breast epithelial cells at 
IC50 concentrations. (n=2) 
 
3.A.4 Reactive oxygen species scavenger NAC reverses DNA damage and apoptosis 
One way in which cells acquire DNA damage is through exposure to reactive 
oxygen species. While ROS typically cause DNA base damage leading to single strand 
DNA breaks, if these breaks are not repaired before replication, they will be converted 
to DNA DSBs [269]. ROS can occur in cells due to normal metabolic activities. Thiols, 
hydoquinones, and flavins can all contribute to ROS due to their ability to undergo redox 
reactions. The mitochondria is another source of ROS production within cells as it 
performs oxidative phosphorylation [270]. Additionally, exposure to environmental 
factors such as chemotherapeutics and radiation can also create ROS. We tested if 
reactive oxygen scavenger NAC could prevent apoptosis. When MDA-MB-231 cells were 
treated with 5 mM NAC, in addition to 5-hydroxy lansoprazole sulfide, there was a 
reduction in the overall amount of apoptosis. This was tested using annexin and 
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propidium iodide staining (Figure 18 A-D) as well as by cleaved PARP and cleaved 
caspase 3 (Figure 19A, C-E). Additionally, 5 mM NAC reduced the amount of γH2AX 
indicating it has a protective effect against DNA DSBs (Figure 19B). Possibly, 5-hydroxy 
lansoprazole sulfide is producing reactive oxygen species causing DNA DSBs. 
 
Figure 18: ROS scavenger NAC abrogates apoptosis in MDA-MB-231 cells treated with 
5-hydroxy lansoprazole sulfide - MDA-MB-231 cells were treated for 72 hours with 
DMSO (A), 10 µM 5-hydroxy lansoprazole sulfide alone (B), and 10 µM 5-hydroxy 
lansoprazole sulfide plus 5 mM NAC (C). Quantification of apoptotic cells is given in D 
using an ANOVA for statistical analysis. (n=3) P<0.05 = *, P<0.01 = **, and P<0.001 = *** 
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Figure 19: ROS scavenger NAC reduces cleavage of PARP and caspase 3 - MDA-MB-231 
cells treated with increasing concentrations of 5-hydroxy lansoprazole sulfide in the 
presence or absence of 5 mM NAC (A). Quantification of γH2AX (B), cleaved PARP (C), 
cleaved caspase 3 (17) (D), and cleaved caspase 3 (19) (E). (n=3) An ANOVA was used to 
compare all groups. P<0.05 = *, P<0.01 = **, and P<0.001 = *** 
 
3.A.5 5-Hydroxy Lansoprazole Sulfide does not produce reactive oxygen species 
The previous data in Figures 18 and 19, would indicate that 5-hydroxy 
lansoprazole sulfide is producing reactive oxygen species that are leading to DNA 
damage and cell death. To confirm that 5-hydroxy lansoprazole sulfide creates reactive 
oxygen species, a 96-well format with CellROX green, to visualize ROS, was used. 
CellROX green is a cell permeable dye that becomes fluorescent once oxidized by ROS 
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and binds to DNA. Menadione, a superoxide generator, was used as a positive control 
and the reactive oxygen scavenger NAC, an L-cysteine source for the biosynthesis of 
glutathione, were also used. As shown in Figure 20A, CellROX is able to detect a 
significant difference between basal treated cells, positive control menadione treated 
cells, and menadione + 5 mM NAC treated cells in both MDA-MB-468 and MDA-MB-231 
using an ANOVA to compare the three treatment groups. Figures 20B and C show that 
lansoprazole at low concentrations did not significantly increase reactive oxygen species 
in MDA-MB-231 cells but did at 4 hours and 6 hours in MDA-MB-468 cells. However, at 
high concentrations, of 200 µM, for a short 2-hour treatment, lansoprazole significantly 
increased reactive oxygen species in both cell lines. Figure 20B and C also show that 5-
hydroxy lansoprazole sulfide does not create reactive oxygen species even at very high 
concentrations of 100 and 200 µM in MDA-MB-468 cells. In fact, high concentrations of 
5-hydroxy lansoprazole sulfide significantly decrease ROS compared to basal cells in 
MDA-MB-468. In MDA-MB-231 cells the was only a significant difference between 5-
hydroxy lansoprazole sulfide and basal at 24 hours, and, while not significant in MDA-
MB-231 cells there is a trend towards a decrease at the higher concentrations of 5-
hydroxy lansoprazole sulfide treatment. This could indicate at high concentrations 5-
hyroxy lansoprazole sulfide is acting as a reactive oxygen scavenger. Further testing 
would need to be performed to confirm this. However, at the lower doses, used in the in 
vitro studies, except for 24 hours in MDA-MB-231 cells, 5-hydroxy lansoprazole does not 
change reactive oxygen species compared basal levels. While MDA-MB-231 cells show a 
significant difference in positive and negative controls there are few treatments that 
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cause a significantly different change in ROS. There are, however, visible trends within 
the data that may indicate a need to further optimize this experiment for MDA-MB-231 
cells or perform repeated experiments. In any case, we can conclude that 5-hydroxy 
lansoprazole sulfide is not causing DNA damage through reactive oxygen species. While 
5-hydroxy lansoprazole sulfide is not causing DNA damage through ROS the use of 5 mM 
NAC reduces the amount of DNA damage after 72 hours as shown in Figure 19A-B. This 
indicates that NAC is having a protective effect. While it is not clear how this may be 
occurring, previous studies in our lab concluded that an increase in γH2AX 
phosphorylation can be caused by a decrease in DNA damage repair pathways alone. 
Potentially, 5-hydroxy lansoprazole sulfide is preventing the repair of DNA damage 
caused by normal cellular processes leading to a build-up of damage and apoptosis.  
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Figure 20: 5-hydroxy lansoprazole sulfide does not produce ROS - (A) Positive and 
negative controls in MDA-MB-231 and MDA-MB-468 cells using CellROX ROS detection 
assay at 2 hours. NAC was used at a concentration of 5 mM. (B) ROS detection in MDA-
MB-231 and MDA-MB-468 cells treated for 2 hours with given concentrations of drugs. 
(C) ROS detection in MDA-MB-231 and MDA-MB-468 cells at 4 hours (red), 6 hours 
(green), and 24 hours (purple).  (n=3, each value is the mean ± SEM) An ANOVA was 
used to compare all groups in each graph. P<0.05 = *, P<0.01 = **, and P<0.001 = *** 
 
3.A.6 5-Hydoxy Lansoprazole Sulfide treatment decreases NHEJ repair activity   
 One way in which cells overcome DNA DSBs is through NHEJ repair [55, 271]. 
NHEJ is an error prone method in which cells can ligate broken ends of DNA. NHEJ is 
initiated by Ku 70 and Ku 80 binding to the broken ends of DNA. This leads to 
recruitment of DNA-PKcs and initiation of DNA damage repair. NHEJ is also controlled by 
PARP expression. One study found that PARP regulates NHEJ by promoting Ku retention 
at sites of DNA DSBs [272]. Furthermore, our lab has shown that PARP expression is 
controlled by FASN [128]. When FASN is inhibited or knockdown there is a decrease in 
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PARP expression. For these reasons, the expression of levels of PARP after treatment 
with lansoprazole and 5-hydroxy lansoprazole sulfide was determined. Both 
lansoprazole and 5-hydroxy lansoprazole sulfide led to a decrease in total PARP 
expression as shown in Figure 15A-B and 15D-E. Additionally, treatment of both MDA-
MB-231 and MDA-MB-468 led to a decrease in the mRNA levels of PARP as shown in 
Figure 21A-B. Our lab has shown that an increase in FASN leads to an increase in PARP 
mRNA and a decrease in FASN leads to a decrease in PARP mRNA [128]. The mechanism 
of this is still unclear and should be further researched in the future. It is possible that 5-
hydroxy lansoprazole sulfide is leading to a reduction in NHEJ via downregulation of 
PARP through inhibition of FASN. 
 
Figure 21: Treatment of MDA-MB-231 and MDA-MB-468 cells with lansoprazole and 5-
hydroxy lansoprazole sulfide reduces mRNA levels of PARP – MDA-MB-231 (A) and 
MDA-MB-468 (B) cells were treated with 10 µM lansoprazole or 5-hydroxy lansoprazole 
sulfide for 72 hours before samples were collected and PARP mRNA levels were 
measured. (n=3) An ANOVA was used for statistical analysis. (n=3) P<0.05 = *, P<0.01 = 
**, and P<0.001 = *** 
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Due to the increase in γH2AX, indicative of DNA DSB, and the decrease in PARP 
the ability of these cells to repair damaged DNA by NHEJ may be impaired after 
treatment with lansoprazole and 5-hydroxy lansoprazole sulfide. While PARP can also 
affect other modes of DNA damage repair (SSB, BER, and NER) which would affect DNA 
damage it was decided to analyze NHEJ due to the presence of DNA DSB and the fact 
that many anti-cancer treatments mediated their effects by causing DNA DSB. Effecting 
the ability of cells to repair DNA through NHEJ may have a significant impact in the 
clinical treatment of cancer.  
Our NHEJ activity assay protocol was adapted from those described in previous 
papers [128, 273]. Figure 22 gives a brief summary of how this assay works. In this assay 
the pGL3 plasmid containing a SV40T promoter is utilized. The plasmid is cut using 
HindIII which produces a linear strand of DNA. The linear strand of DNA separates the 
SV40 promoter from the luciferase gene. In this way the linear plasmid cannot produce 
luciferase. After NHEJ repair, the plasmid will be re-circularized joining the promoter 
with the luciferase gene allowing for signal. In this way we can monitor NHEJ by 
determining the amount of luciferase using an intact pRL-TK, the Renilla plasmid, as a 
transfection efficiency control. Treatment of MDA-MB-231 cells with lansoprazole at 10 
µM concentration did not significantly decrease NHEJ activity while 10 µM 5-hydroxy 
lansoprazole sulfide significantly decreased NHEJ repair (Figure 23A). In MDA-MB-468 
cells both lansoprazole and 5-hydroxy lansoprazole sulfide significantly decreased NHEJ 
repair (Figure 23B). It is not surprising that lansoprazole at 10 µM concentration does 
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not inhibit NHEJ repair in MDA-MB-231 cells due to the high IC50 value to lansoprazole in 
these cells. 
 
Figure 22: Depiction of the NHEJ assay – The pGL3 plasmid is cut between the promoter 
and the luciferase gene using HindIII creating blunt ends. In this linearized form, the 
plasmid is unable to produce luciferase. When the plasmid is repaired and re-
circularized by NHEJ that plasmid will again produce luciferase.  
 
 
Figure 23: 5-Hydroxy Lansoprazole Sulfide decreases NHEJ activity– MDA-MB-231 (A) 
cells and MDA-MB-468 (B) cells treated with 10 µM for 72 hours. (n=3) Statistical 
analysis was performed using an ANOVA. P<0.05 = *, P<0.01 = **, and P<0.001 = *** 
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3.A.7 5-Hydroxy Lansoprazole Sulfide inhibits Fatty Acid Synthesis 
 Previous experiments in our lab have shown that lansoprazole inhibits FASN 
through binding to the TE domain [178]. Upon binding of lansoprazole, activity of FASN 
was decreased as determined by incorporation of radiolabeled acetate into fatty acid 
chains during a 2-hour pulse experiment [178]. All of the above evidence would indicate 
that 5-hydroxy lansoprazole sulfide is working through inhibition of FASN to decrease 
PARP expression, decrease NHEJ repair, and increase DNA damage. To determine if 5-
hydroxy lansoprazole sulfide inhibits FASN activity the end product, free fatty acid 
content, was measured using the free fatty acid quantification kit from Abcam 
(ab65341). To test the ability of the assay to detect differences in fatty acid content 
MDA-MB-436 cells which had vector control or FASN overexpression were utilized. As 
shown in Figure 24A, MDA-MB-436/FASN cells had a significant increase in free fatty 
acids as compared to control MDA-MB-436/Vec cells.  
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Figure 24: 5-hydroxy lansoprazole sulfide treatment reduces the free fatty acid 
content in MDA-MB-231 cells - A) Free fatty acids in MDA-MB-436/Vec vs. MDA-MB-
436/FASN cells (n=3) B) Effect of lansoprazole and 5-hydroxy lansoprazole sulfide on 
free fatty acid content after 72-hour treatment using the IC50 concentrations (n=4). T-
test was used in (A) for statistical analysis and an ANOVA was used in (B). P<0.05 = *, 
P<0.01 = **, and P<0.001 = *** 
 
To test the effect of lansoprazole and 5-hydroxy lansoprazole sulfide on free 
fatty acids, MDA-MB-231 cells were treated with IC50 concentrations of drug for 72 
hours. Cells were collected and counted to normalize to cell number and then the 
amount of free fatty acid was determined. 5-hydroxy lansoprazole sulfide treated cells 
had a significant reduction in free fatty acids (Figure 24B) compared to DMSO control. 
This indicates that 5-hydroxy lansoprazole sulfide is causing a decrease in free fatty acids 
by inhibiting FASN. 
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3.B.8 Summary 
The data indicates that using the metabolite 5-hydroxy lansoprazole sulfide may 
be an effective method for improving the treatment of TNBC. Here, it is shown that 5-
hydroxy-lansoprazole sulfide treatment leads to cellular apoptosis in TNBC. Figure 25 
shows a hypothetical schematic summary of how this is might be occurring. 5-hydroxy 
lansoprazole sulfide inhibits FASN, thereby reducing cellular free fatty acids. This 
inhibition leads to a decrease in PARP and ultimately to a decrease in NHEJ activity. 
While it is not clear what the mechanism is for reduction of PARP, it is possible that end 
product starvation, palmitate, or FASN enzyme itself is playing a role in reduced 
transcription of PARP. While it is not clear how DNA damage is occurring, it is possible 
that DNA damage is occurring due to a decrease in NHEJ repair and the cells failing to 
repair damage that occurs due to normal cellular activity and DNA decay. Additionally, 
5-hydroxy lansoprazole sulfide causes apoptosis through activation of caspase 3 and 
potentially necroptosis. Use of the reactive oxygen species scavenger NAC leads to a 
reduction in DNA damage and apoptosis. While this could suggest that the DNA damage 
is leading to apoptosis it is also possible that ROS scavenging is playing another role in 
the prevention of apoptosis (see discussion). 
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Figure 25: Hypothetical schematic of pathway – 5-hydroxy lansoprazole sulfide inhibits 
FASN causing a reduction in PARP and NHEJ repair. Reduction in NHEJ leads to an 
increase in DNA damage. Treatment with 5-hydroxy lansoprazole sulfide leads to 
apoptosis. The exact mechanism of how caspase 3 is activated by 5-hydroxy 
lansoprazole sulfide remains to be elucidated. Potentially, mitochondrial membrane 
dysfunction or activation of p53 family members may be playing a role as has been 
observed in the literature (see discussion). Further studies are required to confirm the 
mechanism. 
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Section 3.B CC-115 
3.B.1 FASN does not play a role in resistance to DNA-PK inhibitor Nu7441 or CC-115 
 This thesis has shown that FASN affects NHEJ repair. Previous studies in our lab 
have shown that FASN increases NHEJ repair by increasing recruitment of Ku proteins to 
the site of DNA damage and increasing DNA-PK activity [229]. It is estimated that there 
are about 10 DNA DSB per day in dividing mammalian cells caused by cleavage of 
nuclear enzymes, DNA replication errors, ROS, and ionizing radiation [55]. Additionally, 
many chemotherapeutics aim to produce DNA DSBs as a way to target cancer cells 
[274]. Inhibition of DNA-PK is an emerging field with inhibitors in clinical trials to 
improve patient outcomes. With any treatment, the development of resistance will 
hinder efficacy of a drug. If FASN effects the activity of DNA-PK, it could therefore lead 
to resistance in DNA-PK inhibitors. For these reasons, we hypothesized that FASN 
contributed to resistance to CC-115 by increasing DNA-PK activity.  
To investigate the potential mechanism of CC-115 resistance, I first took 
advantage of MCF7/AdVp3000 (M3K) cell line, which was selected for Adriamycin 
resistance. M3K cells harbor multiple mechanisms of drug resistance, including 
overexpression of FASN [122], and we tested their response to CC-115 in comparison 
with its parental MCF7 cells. As shown in Figure 26A and B, M3K cells are about 44 times 
more resistant than parental MCF7 cells to CC-115 with IC50 of ~2.2 µM and ~50 nM, 
respectively. 
 Due to the fact that CC-115 inhibits DNA-PK and FASN increases DNA-PK activity 
in M3K cells [128], it is possible that FASN overexpression in M3K cells contributes to CC-
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115 resistance. To test this possibility, we took advantage of MCF7 cells with stable 
overexpression of FASN (MCF7/FASN) and M3K cells with stable FASN knockdown 
(M3K/shFASN) (see Figure 26C) and tested their response to CC-115 in comparison with 
their respective control cells (MCF7/Vec and M3K/Scr). As shown in Figure 26A, D and E, 
ectopic FASN overexpression or FASN knockdown did not influence cellular response to 
CC-115. Thus, FASN may not contribute to CC-115 resistance via its DNA-PK inhibitory 
activity. Additional cell lines tested, while having slightly higher resistance than MCF7 
cells, did not have a significant resistance. (Figure 26A) 
CC-115 is a dual mTOR/DNA-PK inhibitor, therefore, to confirm that DNA-PK 
inhibition is not part of the resistance due to FASN expression, we also tested a DNA-PK 
selective inhibitor, NU7441. As shown in Figure 27A-D, alteration of FASN expression did 
not change cellular response to NU7441 albeit M3K cells are slightly more resistant to 
NU7441 than the parental MCF7 cells, this was not significant and could be due to other 
difference between MCF7 and M3K and not FASN. There was also no difference in 
sensitivity between all additional cell lines tested (Figure 27A). 
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Figure 26: FASN does not affect the potency of CC-115 - A) IC50 values to dual DNA-
PK/mTOR inhibitor CC-115 determined by methylene blue in each cell line. (n=3) B) 
Survival curve for MCF7 (■) and M3K (●) cells treated with CC-115. C) FASN expression 
in MCF7/Vec, MCF7/FASN, MCF7, M3K, M3K/Scr, and, M3K/shFASN cell lines. Survival 
curves for D) M3K/Scr (●) vs. M3K/shFASN (■) and E) MCF7/Vec (■) and MCF7/FASN (●). 
An ANOVA was used for statistical analysis in (A), followed by a T-test to compare MCF7 
(parent) to M3K (Doxorubicin resistant clone). P<0.05 = *, P<0.01 = **, and P<0.001 = 
*** 
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Figure 27: FASN does not affect the potency of DNA-PK specific inhibitor NU7441 - A) 
IC50 values to DNA-PK inhibitor Nu7441 determined by methylene blue. Survival curves 
for (n=3) B) MCF7 (■) and M3K (●), C) M3K/Scr (●) and M3K/shFASN (■), and D) 
MCF7/Vec (■) vs MCF7/FASN (●). An ANOVA was performed on (A) and no statistically 
significant difference was found.  
 
Being that CC-115 is a dual mTOR/DNA-PK inhibitor, we next tested if its inhibition 
of mTOR pathway was impaired in the drug resistant M3K cells. To do this we treated cells 
for 2-hours and monitored for phosphorylation of certain proteins. Specifically, we 
probed for phosphorylation at Thr389 on S6K, which is indicative of phosphorylation by 
mTOR, and Ser235/236 on S6, indicative of phosphorylation by S6K [214]. As shown in 
Figure 28A, CC-115 inhibition of constitutive activation of S6K and phosphorylation of S6, 
downstream targets of mTOR, were significantly impaired in M3K compared with MCF7 
cells. The western blot for S6K and P-S6K has two bands because the antibody can also 
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detect p85. Based on these findings, we conclude that FASN does not play a role in DNA-
PK inhibitor resistance. 
 
3.B.2 Identification of ABCG2 as a contributor to CC-115 resistance  
 Due to the short treatment in the above study, lack of mTOR inhibition, 50-fold 
increase in resistance, and, the known role of efflux pumps in resistance [275-278], we 
decided to determine if an efflux pump could be playing a role in this resistance. First, it 
has been previously shown that M3K cells overexpress ABCG2 [279]. We also tested the 
expression of ABCB1 and ABCC1 shown in Figure 28B. This matched with early studies 
which indicated M3K acquired resistance through overexpression of ABCG2 and not 
ABCB1 and ABCC1 [280].  
 
Figure 28: CC-115 inhibition of mTOR and expression profile of efflux pumps - A) CC-
115 inhibition of mTOR, monitored by phosphorylation of S6 and S6K. B) Expression 
profile of ABCB1, ABCC1, and ABCG2. (S6K and P-S6K also detects p85) 
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To determine cellular accumulation of CC-115, I first had to determine if CC-115 
was a fluorescent molecule. To do this, I used spectrophotometer with a small amount 
of sample (0.33mM) and measured the absorbance at different wavelengths along the 
spectrum. Based on the absorbance shown in Figure 29A CC-115 absorbs light at about 
340-400 nm. Knowing this absorbance allowed me to use a fluorescence 
spectrophotometer (Cary Eclipse Varian) and measure the emission at a specific 
excitation wavelength. Excitation at a wavelength of 386 nm yielded the emission 
spectra shown in Figure 29B. The fluorescent property of CC-115 provides the 
opportunity of using flow cytometry to measure cellular accumulation of drug.  
 
Figure 29: Absorbance and Fluorescence of CC-115 - A) Absorbance spectrum for CC-
115 B) Emission spectrum at excitation 386 nm.  
 
To test the ability of flow to measure differences in accumulation of CC-115 I first 
tested DMSO control versus CC-115 treatment in MCF7 cells. Using the excitation and 
emission data for CC-115, it was decided with help from the flow cytometry lab to use 
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BD LSR II analyzer at excitation wavelength of 405 nm and an emission of 421 nm. Cells 
were treated with 10 µM CC-115 or DMSO as a control for 30 min. After 30 min cells 
were collected and washed with PBS. Cells were then resuspended in 500 µL PBS and 
filter through 5 mL polystyrene round-bottom tube with cell-strainer cap for flow 
cytometry. Using these parameters, we could see a significant difference in fluorescence 
intensity of MCF7 cells exposed to drug versus DMSO control. This is shown in Figure 
30A and B. Furthermore, there was a significant difference in CC-115 accumulation 
between MCF7 and M3K cells. This is shown in Figure 30C and D, M3K cells accumulated 
about ~20% the amount of CC-115 as was seen in MCF7 cells. Here, only MCF7 treated 
with DMSO as a negative control is shown due to the overlap of MCF7 and M3K negative 
controls. 
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Figure 30: CC-115 Accumulation is decreased in M3K cells as compared to MCF7 - 
Accumulation of CC-115 can be detected in cells with flow cytometry using excitation 
wavelength 405 nm and emission max filter at 421 nm. A) shows the separation of cells 
treated with CC-115 versus those treated with DMSO control and B) is the quantification 
of the fluorescence intensity. Panel C) shows an increase in accumulation of CC-115 in 
MCF7 cells as compared to less accumulation in M3K cells with quantification in D. (n=3) 
Statistical analysis using a T-test comparing negative and positive controls in (C) and 
ANOVA comparing all groups (D) was utilized. P<0.05 = *, P<0.01 = **, and P<0.001 = 
*** 
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3.B.3 Inhibition of ABCG2 reverses CC-115 resistance by increasing accumulation of 
drug 
To evaluate the role of ABCG2 in the efflux of CC-115, we employed the use of 
two ABCG2 inhibitors: fumitremorgin C (FTC) [257], which is commercially available, and 
C8, an inhibitor developed in our lab [259]. First, the inhibitors were used to measure 
the accumulation of CC-115 within M3K cells treated with 1 µM and 5 µM inhibitor. 
Cells were collected and incubated with inhibitor for 15 minutes before exposure to CC-
115 for 30 min. As shown in Figure 31A-C, there was a dose dependent increase in CC-
115 accumulation in M3K cells. As discussed above, M3K cells had about a 79% decrease 
in CC-115 accumulation as compared to MCF7 cells. When M3K cells are first treated 
with 1 µM and 5 µM C8 this decrease was reduced to ~45% and ~14% respectively. 
Treatment with FTC had a similar effect with a decrease of only ~30% and ~0.5% with 1 
µM and 5 µM, respectively. 
 96 
 
Figure 31: ABCG2 decreases cellular accumulation of CC-115 - CC-115 accumulation in 
M3K cells was measured after inhibition of ABCG2 by C8 (A) and FTC (B) using 1 µM and 
5µM concentration of inhibitor. C) Quantification of CC-115 accumulation. (n=3) An 
ANOVA comparing all groups was used in (C) for statistical analysis. P<0.05 = *, P<0.01 = 
**, and P<0.001 = *** 
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 Furthermore, ABCG2 inhibition by C8 sensitized M3K cells to CC-115 inhibition of 
mTOR signaling (Figure 32A). M3K cells treated with 1 µM of C8 in combination with 
increasing concentrations of CC-115 for 2 hours decreased S6K and S6 phosphorylation. 
Inhibition of ABCG2, using 1 µM C8 or FTC, in a methylene blue assay lead to a 10-fold 
decrease in IC50 value in M3K cells (Figure 32B and C).  Treatment with 1 µM C8 or FTC 
alone did not affect growth of M3K cells as evidenced by similar proliferations rates as 
control. 
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Figure 32: Inhibition of ABCG2 sensitizes M3K cells to CC-115 and increases inhibition 
of mTOR signaling - A) Western blot measuring mTOR activation through P-S6K and P-S6 
in the absence or presence of 1 µM C8 B) Sensitization of M3K cells to CC-115 treatment 
in the presence of 1 µM FTC or C8 C) Potency index to CC-115 in M3K cells treated with 
vehicle (●), C8 (▼) and FTC (■) at 1 µM. (n=3) ANOVA was utilized in (B) to determine 
statistical significance. P<0.05 = *, P<0.01 = **, and P<0.001 = *** 
 
3.B.4 Overexpression of ABCG2 in MCF7 and HEK293 cells increases resistance to CC-
115 
 To further validate ABCG2’s role in CC-115 efflux and resistance HEK293/Vec vs 
HEK293/ABCG2 and MCF7/Vec vs MCF7/ABCG2 (Figure 33A) were generated. HEK293 
cells were transfected with a venus tagged ABCG2 for better visualization. A western 
blot confirming overexpression of ABCG2 in these cell lines is in Figure 33A. The IC50 to 
CC-115 was then determined by MTT and methylene blue respectively. Both ABCG2 
overexpression cell lines had a significant increase in resistance to CC-115 treatment 
(Figure 33B and C). Then accumulation of CC-115 was measured in the different cell 
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lines using FACs. Figure 33D and E shows that both HEK293/Vec and MCF7/Vec had a 
greater accumulation of drug as compared to their paired counterparts HEK293/ABCG2 
and MCF7/ABCG2. The ability of CC-115 to inhibit the mTOR pathway was again 
measured by phosphorylation of S6K and S6 (Figure 34A-B). HEK/ABCG2 and 
MCF7/ABCG2 required more drug to achieve the same amount of inhibition as was seen 
in their vector control cells respectively. 
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Figure 33: Overexpression of ABCG2 in HEK293 and MCF7 cells reduces accumulation 
increases resistance to CC-115 - A) Expression of efflux pumps ABCB1, ABCC1, and 
ABCG2. (ABCG2 in HEK293 cells is venus tagged increasing its molecular weight) B) IC50 
to CC-115 in HEK293/Vec vs HEK293/ABCG2 by MTT and MCF7/Vec vs MCF7/ABCG2 by 
methylene blue Assay. C) Representative survival curve for Vec (●) and ABCG2 (■) 
overexpression cells treated with CC-115 in HEK293 and MCF7. D) and E) CC-115 
accumulation measured by flow cytometry with quantification. (n=3) Statistical analysis 
using a T-test comparing IC50 to CC-115 in Vec and ABCG2 overexpressing cells (B) and 
relative accumulation (D) was used to determine significance. P<0.05 = *, P<0.01 = **, 
and P<0.001 = *** 
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 Figure 34: ABCG2 increases resistance to CC-115 inhibition of mTOR - A) CC-115 
inhibition of mTOR in HEK293 cells and B) MCF7 cells. Cells were treated with CC-115 for 
2 hours and then cell pellets were collected for analysis. (n=4) 
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To confirm ABCG2’s role in CC-115 resistance HEK293/ABCG2 cells were used 
with ABCG2 inhibitors. The HEK293/ABCG2 cells were chosen based on ABCG2 
expression levels confirmed via western blot analysis. ABCG2 expression in 
MCF7/ABCG2 was much lower than that observed in M3K and HEK293/ABCG2 cells 
(Figure 35). MCF7/ABCG2 cells while still having a significant difference in IC50, about 2-
fold, and accumulation of CC-115, reduction of about 21%, it was much less than was 
observed for M3K cells at 79%. Due to the lower expression of ABCG2 it may be hard to 
see a significant difference when using inhibitors. Additionally, HEK293/ABCG2 cells 
showed about a 45% reduction in accumulation in CC-115 as compared to M3K cells, 
79%. M3K cells were acquired by stepwise selection and may have additional changes 
occurring within the cells that may increase resistance other than ABCG2 expression. 
Furthermore, it is known that ABCG2 in M3K cells carries an arginine to threonine 
mutation at position 482 [281] which may increase its ability to efflux CC-115.  
 
Figure 35: ABCG2 expression (ABCG2 in HEK293 cells is venus tagged increasing its 
molecular weight) 
 
 103 
Using the same method as above HEK293/ABCG2 cells were pre-incubated with 
1 µM and 5 µM C8 or FTC for 10 min and then 10 µM CC-115 was added for 30 min to 
measure accumulation. As shown in Figure 36A-C there was a dose dependent increase 
in CC-115 accumulation with inhibition of ABCG2 by either inhibitor. Introducing either 1 
µM C8 or FTC into the IC50 assay (MTT) caused a sensitization to CC-115 treatment 
(Figure 37B and C). Inhibition of the mTOR pathway was also reduced with addition of 1 
µM C8. This was determined by again measuring the phosphorylation of S6k and S6 
(Figure 37A). 
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Figure 36: Inhibition of ABCG2 in HEK293 cells restores CC-115 accumulation - A) and 
B) dose response to ABCG2 inhibitors C8 and FTC, using 1µM and 5 µM, in restoring CC-
115 accumulation in HEK293/ABCG2 cells with quantification C). (n=3) An ANOVA 
comparing all groups was used in (C) for statistical analysis. P<0.05 = *, P<0.01 = **, and 
P<0.001 = *** 
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Figure 37: Inhibition of ABCG2 in HEK293 cells reverses mTOR inhibition and sensitizes 
HEK293/ABCG2 to CC-115 - A) Analysis of CC-115 inhibition of mTOR using ABCG2 
inhibitor C8 at a concentration of 1 µM by western blot B) Sensitization to CC-115 
treatment in HEK293/ABCG2 cells using ABCG2 inhibitors C8 and FTC at 1 µM 
concentration. C) Representative survival curve of HEK293/ABCG2 cells treated with CC-
115 - vehicle (●), C8 (▼) and FTC (■) at 1 µM. (n=3) An ANOVA comparing all groups in 
(B) was utilized for statistical analysis. P<0.05 = *, P<0.01 = **, and P<0.001 = *** 
 
3.B.5 CC-115 is also a substrate of ABCB1 
It is known that ABC transporters involved in drug resistance have overlapping 
substrates, therefore, we next tested if other ABC transporters such as ABCB1 may also 
contribute to CC-115 resistance. For this purpose, we took advantage of MCF7 cells that 
overexpress ectopic ABCB1 (BC19 cells) (Figure 38A) and tested CC-115 accumulation 
and resistance compared with vector-transfected MCF7 cells (MCF7/Vec). As shown in 
Figure 38B-C, CC-115 accumulation is significantly reduced in BC19 compared with the 
control MCF7/Vec cells. The IC50 of CC-115 was also significantly increased in BC19 cells 
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compared with the MCF7/Vec cells. (Figure 38D-E) Thus, ABCB1, in addition to ABCG2, 
may also contribute to CC-115 resistance by reducing its intracellular accumulation. 
 
Figure 38: CC-115 is a substrate for ABCB1 - A) Expression of ABCB1. B) and C) 
Accumulation of CC-115 in MCF7/Vec versus MCF7/BC19 with D) IC50 to CC-115 in MCF7 
with Vec or ABCB1 overexpression. E) Representative survival curve for MCF7 cell 
treated with CC-115 – Vec (●) and ABCB1 (■). (n=3) Statistical analysis was performed 
using a T-test to compare relative accumulation (B) and IC50. P<0.05 = *, P<0.01 = **, 
and P<0.001 = *** 
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3.B.6 Summary  
Here we identified a mechanism of resistance that can be utilized by cancer cells 
to overcome the drug CC-115, which is currently in clinical trials. ABCG2 removes CC-115 
from within cells preventing its interaction with target proteins as shown by a lack of 
mTOR inhibition. Inhibition of ABCG2 using small molecule inhibitors C8 and FTC 
increased accumulation of CC-115 and increased the inhibition of mTOR in cells with 
overexpression of ABCG2. While ABCG2 has been identified as a mechanism of 
resistance for a variety of anticancer drugs there is still no clinically approved drug 
inhibiting its activity. However, ABCG2 status can be assessed to stratify patients into 
treatment groups. Additionally, ABCB1 a second efflux pump, removes CC-115 from cells 
and may also be contributing to resistance. 
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CHAPTER 4: DISCUSSION 
Section 4.A: 5-hydroxy lansoprazole Sulfide 
Currently, FDA-approved PPI’s could be quickly implemented in the treatment of 
TNBC. In a current clinical trial, patients are receiving 80 mg omeprazole twice a day 
which is four times the optimal dose in the treatment of Helicobacter pylori [282]. While 
PPI’s may be effective, if 5-hydoxy lansoprazole sulfide is largely responsible for the 
positive effects, it may be most beneficial to directly give patients this compound. The 
use of 5-hydroxy lansoprazole sulfide in the treatment of TNBC could prove to be 
beneficial; however, there are many obstacles that will need to be overcome and 
addressed first. The major obstacle will be the delivery method of 5-hydroxy 
lansoprazole sulfide. Pharmacokinetic studies in mouse models will need to be utilized 
to determine the best route of administration, half-life, and elimination. Additionally, 
while lansoprazole has been FDA-approved, indicating there are acceptable side effects, 
its metabolite, 5-hydroxy lansoprazole sulfide, has not. Even though it seems 
counterintuitive that there would be additional side effects from 5-hydroxy lansoprazole 
sulfide over lansoprazole, that may not be the case. Only about 15-25% of lansoprazole 
is converted to the 5-hydroxylated metabolite and excreted in the urine [283, 284]. 
Therefore, a maximum tolerated dose will need to be determined to insure there are no 
ill effects from using 5-hydroxy lansoprazole sulfide at higher concentrations than are 
typically seen in the body when using parent compound lansoprazole. Once an effective 
administration route and MTD is determined, the effect of 5-hydroxy lansoprazole 
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sulfide treatment on TNBC will need to be assessed in xenograft mouse models of this 
disease.  
The use of 5-hydroxy lansoprazole sulfide may also be an effective treatment 
strategy for cancer cells that have defects in other DNA repair pathways, such as 
mutations in BRAC1/2, leading to defects in the homologous repair mechanism. Due to 
the inhibition of NHEJ caused by 5-hydroxy lansoprazole sulfide, cells that have known 
defects in HR may be more sensitive to treatment and be susceptible to synthetic 
lethality. This has been observed in cells using PARP inhibitors [285]. For this reason, it 
may be important to look at the effect in other cancers. Furthermore, the synergistic 
effect of 5-hydroxy lansoprazole sulfide with current chemotherapy, doxorubicin, will 
need to be assessed. This can be done first in cell lines and, then, with promising results, 
could be moved into a mouse model of TNBC. 
During experimentation, as shown in Figure 8, it was observed that there was a 
difference in response to lansoprazole and 5-hydroxy lansoprazole sulfide in TNBC but 
not in luminal A MCF7 cells. While it is unclear if this is due to differences between TNBC 
and luminal A type breast cancers, another intriguing possibility is differences in CYP 
enzymes within these cell lines. While CYP enzymes are mostly expressed in the liver, 
they are also expressed in cancer tissues. One study showed that there are differences 
in expression of CYP enzymes between paired benign and cancer tissues and that these 
changes may play a role in cancer cell survival by either eliminating toxins or preventing 
prodrugs from being converted to their active metabolite at the tumor site [286, 287]. 
Differences in expression profiles of CYPs in breast cancer showed that expression could 
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be clustered into different ethnic groups [288]. However, further studies are required to 
determine if this creates differences in clinical outcome. Studies have shown that 
changes in CYP2D6 efficiency has an effect on clinical outcomes of breast cancer 
patients. Tamoxifen is typically given as an antiestrogen in the case of estrogen receptor 
positive breast cancer [289]. While tamoxifen does have some activity against the 
estrogen receptor, its metabolite, endoxifen, formed from CYP3A4 and CYP2D6, is 100 
times more potent [290]. Women with mutations in CYP2D6, which cause decreased 
activity, were more likely to have relapse of their breast cancer over those who showed 
normal activity of CYP2D6 [291]. Additionally, a retrospective study looking at the use of 
CYP2D6 inhibitors and tamoxifen treatment concluded that the benefits of tamoxifen 
were significantly decreased with concurrent use [292]. While we did not test the CYP 
profile in the cell lines used in this thesis, this might be a direction to take this research 
in the future. A genome-wide approach showed that there was an association between 
TNBC and CYP2C19 deletion [293]. It is possible that the CYP profile in TNBC differs from 
that in luminal A breast cancer cell lines. If this is the case, MCF7 may convert the parent 
compound to 5-hydroxy lansoprazole sulfide more efficiently than TNBC cell lines, 
creating a similar effect as the parent compound.  
To test this possibility, it is important to first check the expression of different 
CYP’s and also to determine if there are any mutations which might affect activity. While 
expression may not be changed there are known mutations that can increase or 
decrease CYP activity which will have an effect on drug conversion [294]. While this is 
one possibility for the difference in luminal A versus TNBC it may not be the only 
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explanation. 5-hydroxy lansoprazole sulfide may be more effective in TNBC because it is 
leading to synthetic lethality similar to that seen in cells with mutations in HR. This could 
be a factor in MDA-MB-436 and HCC1937 cell lines as both harbor a mutation in BRCA1. 
Additionally, some cell lines will exhibit a ‘BRCAness’ phenotype in which they display 
similar features of cells with mutations in BRCA1 but the exact cause of the phenotype 
may not be known [295]. While the two main cell lines used in this work, MDA-MB-231 
and MDA-MB-468, do not carry any known mutations in HR pathway, studies have 
shown that treatment with specific agents can cause a conversion to a ‘BRCAness’ state 
[296-298]. This leaves the possibility that 5-hydroxy lansoprazole sulfide may also be 
affecting HR in TNBC and well as NHEJ leading to synthetic lethality. Furthermore, a 
study of TNBC ‘BRCAness’ in 3 different patient cohorts looked at BRCA1 mutation 
status, BRCA1 methylation patterns, and a specific BRCA-1 like pattern by comparative 
genomic hybridization found that the majority of TNBC exhibit a ‘BRCAness’ phenotype. 
Therefore, it is possible that TNBC is more sensitive to treatment due to this feature. 
The ‘BRCAness’ status in these cell lines after treatment with 5-hydroxy lansoprazole 
sulfide should therefore be assessed. 
FASN regulation of PARP expression is a relatively new concept and has not been 
fully explored. While it is currently unknown how this may be occurring, there are a few 
possibilities. It is possible that the FASN molecule itself is somehow interacting with 
transcription factors involved in regulation of PARP such as SP1 [299], AP-2 [300], YY1 
[301], and Ets [302]. It is also possible that FASN itself does not interact with these 
transcription factors, but, rather, its end-product, palmitate, could be affecting the 
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activity of one of these transcription factors. Further studies are necessary to determine 
how this phenomenon might occur. The first experiment to be performed to determine 
how this might be occurring would be to look at expression levels of these transcription 
factors when FASN is overexpressed and knocked down in different cells lines. Addition 
of a gene reporter activity assay for these promoters will indicate which transcription 
factors are activated by FASN overexpression and knockdown. A pull-down experiment 
could be used to see if FASN directly interacts with SP1, AP-2, YY1 or Ets. Furthermore, 
FASN may not directly interact with these transcription factors but rather, its end 
product, palmitate, could be used to modify these transcription factors increasing 
activity or affect its expression. One way to determine if regulation is occurring by end 
product starvation is to supplement the media with palmitate in cells with FASN 
inhibition to determine if this will reverse the observed decrease in PARP after FASN 
inhibition.  Additionally, our previous paper indicates that FASN may also be affecting 
PARP expression by relieving NF-kB inhibition on PARP transcription [128]. Therefore, 
NF-kB expression and activity should also be assessed in the same way. These tests will 
also help to determine if FASN is not regulating PARP expression. It is possible that the 
decrease observed in PARP protein levels is due to PARP cleavage and not a decrease in 
expression. Additionally, while mRNA data indicates that PARP transcription is 
decreasing this could be caused by the late, 72-hour, analysis time. Cells that are being 
treated with drug are starting to die at 72 hours which would affect transcription and 
potentially that is why there was a decrease. These experiments should be run again at 
24 and 48 hours to see if the same result is obtained.  
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Based on this data, it appears that 5-hydroxy lansoprazole sulfide prevents the 
repair of DNA DSBs potentially through regulation of PARP expression. If this is the case, 
while inhibition of DNA DSBs plays a role in cell death, a decrease in PARP expression 
can also affect other DNA repair pathways. PARP plays a significant role in single strand 
DNA break repair, base excision repair (BER), and nucleotide excision repair (NER) [303-
305]. BER is typically utilized by cells to remove damage caused by oxidation, alkylation, 
and deamination [306]. These types of DNA lesions can occur via ROS, environmental 
factors, radiation, or a natural result of DNA decay [307]. On the other hand, NER 
removes bulky DNA lesions such as inter- and intra- DNA crosslinks created by UV 
irradiation and chemotherapeutics [308, 309]. While activity of these pathways was not 
tested, a decrease in PARP expression may not only be affecting NHEJ but also these 
other forms of DNA repair leading to increase in DNA damage, mutation, and cell death.  
It is possible that the increase in DNA DSBs observed after treatment of 5-hydroxy 
lansoprazole sulfide may be caused by cells not repairing damaged bases or removing 
bulky adducts.  
One way in which DSBs can arise is through reactive oxygen species causing 
damage to DNA bases, which, when not repaired can be converted to DSBs during 
replication. While it is possible 5-hydroxy lansoprazole sulfide causes DNA damage via 
another mechanism it is clear that 5-hydroxy lansoprazole sulfide itself is not producing 
reactive oxygen species. It is also possible that 5-hydroxy lansoprazole sulfide does not 
produce DNA damage at all but rather the DNA damage is due to the inhibition of NHEJ 
repair. DSBs created by reactive oxygen species produced by normal metabolic activity 
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are unable to be repaired, leading to their accumulation. This could be due to ROS or it 
could be due to natural DNA decay failing to be repaired. Previous studies have 
indicated that cells with deficient NHEJ repair develop spontaneous DNA DSBs [310, 
311]. DNA DSB can arise naturally in the cell by DNA decay or by the production of 
reactive oxygen species during normal metabolic processes [269, 312, 313]. In 
replicating MEFs, it has been shown that DNA damage caused by oxidative stress led to 
cellular senescence [314]. Cells with a defect in DNA repair pathways reached their 
replicative limit quicker than wild-type cells, implicating repair mechanisms as a way in 
which cells overcome oxidative damage. Oxidative stress still occurs in non-replicating 
cells. In MEFs and primary human fibroblasts defective in some aspect of NHEJ repair, 
there was an increased accumulation of γH2AX over time [269]. To confirm cells with 
deficiencies in NHEJ repair did not have increase γH2AX due to an increase in ROS, 
fibroblasts lacking glutathione synthetase were utilized as a positive control for ROS and 
oxidation of proteins was monitored. Cells with defects in NHEJ repair did not have an 
increase in oxidation of proteins as compared to control. This indicated that there is not 
an increase in ROS as compared to WT and suggests that the DNA damage is occurring 
due to the cells inability to repair damaged DNA. Additionally, the glutathione 
synthetase lacking fibroblasts did not have an increase in γH2AX over time. This may be 
due to an active WT NHEJ repair pathway.  
Furthermore, in addition to fibroblasts, neuronal cells that do not have a 
functioning NHEJ repair pathway begin to show an increase in chromosomal breaks over 
time. These lesions led to an apoptotic event [312]. Based on this data, it is possible that 
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the inhibition of NHEJ by 5-hydroxy lansoprazole sulfide leads to an increase in DNA 
DSBs due to the inability of these cells to repair damage caused by reactive oxygen 
species produced by normal cellular metabolic activity. This provides one possible 
explanation for the protective effect NAC has on both preventing DSBs, as indicated by 
γH2AX, and against apoptosis in cells treated with 5-hydroxy lansoprazole sulfide. The 
NAC may protect cells against reactive oxygen species produced during normal 
metabolic activity.  
It is also possible that 5-hydroxy lansoprazole sulfide is leading to DNA damage 
via other means, and reactive oxygen scavenger NAC is protective in some other way. 
For example, ROS have also been implicated in mediating apoptosis within cells. Cell 
death by apoptosis can be triggered by things like DNA damage, ROS, hypoxia, and heat 
shock [315]. Specifically, ROS has been shown to induce apoptosis through both intrinsic 
and extrinsic pathways [316]. ROS can lead to activation of p53 and, ultimately, to an 
increase in pro-apoptotic bcl-2 proteins, as well as causing oxidation of cardiolipin 
releasing cytochrome C and causing mitochondrial depolarization. Additionally, ROS can 
activate death receptors on the membrane, leading to apoptosis through the extrinsic 
pathway [317]. NAC could also have a protective effect in cells by preventing activation 
of these pathways by ROS scavenging and not just by preventing DNA damage. 
Additionally, NAC has a reactive thiol group that could also be interacting with 5-
hydroxy lansoprazole sulfide preventing its antitumor activities [318]. In this way NAC 
helps to prevent DNA damage and apoptosis by inactivating 5-hydroxy lansoprazole 
sulfide rather than by reducing ROS. To determine if this inactivation is in fact occurring, 
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a nonthiol antioxidant could be utilized to see if the same results are obtained for DNA 
damage and apoptosis. These antioxidants include MnTBAP, butylated hydroxyanisole, 
mannitol, and Trolox. 
There were observed differences in cancer cells versus benign epithelial cell lines 
in terms of DNA damage caused and IC50 values. Benign epithelial cell lines did not have 
an induction of gH2AX and there was about a 2.5-fold increase in IC50 to 5-hydroxy 
lansoprazole sulfide. Due to the inhibition of FASN by 5-hydroxy lansoprazole sulfide, the 
differences observed between cancer and benign cells may be caused by differences in 
metabolic activities within these cells. It is known that cancer cells take up a large amount 
of glucose and utilize this glucose in anaerobic respiration to produce energy, while non-
cancerous cells utilize aerobic respiration. These differences in metabolic activity could 
account for differences in reactive oxygen species and the amount of DNA damage 
produced when cells are treated with 5-hydroxy lansoprazole sulfide. 
 
Section 4.B: CC-115 
In this study, we showed that ABCG2 expression plays a major role in CC-115 
resistance by reducing its intracellular accumulation and its inhibition of mTOR pathway. 
ABCB1, to a lesser extent, may also contribute to CC-115 resistance via a similar 
mechanism. Clearly, CC-115 may be a substrate of multiple ABC transporters, and reduced 
clinical responses are expected in patients that express any of these ABC transporters. 
Based on these findings, it is tempting to speculate that ABCG2 and ABCB1 may 
be utilized as markers to stratify patients into treatment groups for future clinical trials. 
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The observed variability in CLL patient response in a past trial may possibly be due to 
different expression of ABCG2 or ABCB1. Previously, it has been found that ABCG2 and 
ABCB1 are expressed in leukemia patients by comparing expression levels in cancer 
patients and healthy donor controls. Their expression influences the outcome of these 
patients who were subjected to chemotherapy [319-321].  Currently, there is an ongoing 
clinical trial of CC-115 for glioblastoma. However, it is also well known that ABCG2 and 
ABCB1 are both highly expressed in the endothelial cells of the blood brain barrier 
preventing drug entry [236], which may affect the outcome of this trial. Unfortunately, 
there are no FDA-approved drugs to target ABCG2 or ABCB1, due to neurotoxicity, low 
specificity, and unachievable clinical IC50 [322]. While FTC cannot be used in the clinic due 
to neurotoxicity, C8 has not moved passed in vitro studies [259].  Further in vivo studies 
would need to be conducted to access pharmacokinetic properties before testing in a 
clinical setting. Lack of clinically available inhibitors limits combined treatment strategies 
for patients with ABCG2 or ABCB1 overexpression and efforts have shifted to produce 
new treatments that are not substrates for these efflux pumps [323]. 
Despite the fact that FASN up-regulates DNA-PK activity [229], FASN over-
expression does not appear to contribute to cellular resistance to the DNA-PK inhibitory 
activity of CC-115 or a DNA-PK selective inhibitor, NU7441. We have proven that FASN 
over-expression causes resistance to DNA damaging drugs [126] and inhibitors of PARP1 
(manuscript submitted), a mediator of FASN-induced up-regulation of DNA-PK activity 
[229]. Although it remains to be determined, the failure of FASN over-expression in 
resistance to DNA-PK inhibition may be due to the fact that FASN overexpression only 
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leads to an increase in activity and not expression of DNA-PK, which may be insufficient 
to overcome the effect of DNA-PK inhibition.  
 
Future Directions 
 Based on this work, there are a few directions and loose ends that should be 
addressed. First, as discussed above, the expression levels of CYP3A4 and CYP2C19 may 
be able to explain the difference in sensitivity to lansoprazole and 5-hyroxy lansoprazole 
sulfide. Knowing this information in a patient population can help to predict the most 
effective treatment strategy. Second, while this thesis shows that 5-hydroxy 
lansoprazole sulfide causes apoptosis, the exact mechanism of how this is occurring is 
still unknown. It is also possible that 5-hydroxy lansoprazole sulfide is causing cell death 
through other pathways such as necroptosis. In the case of apoptosis, it would be 
interesting to see if the DNA damage created by 5-hydroxy lansoprazole sulfide is 
causing activation of p53 and, then, when cells are unable to repair DNA, there is a 
upregulation of pro-apoptotic proteins such as Bak and Bax [324]. Expression of these 
pro-apoptotic proteins could be the mechanism behind apoptosis caused by 5-hydroxy 
lansoprazole sulfide inducing mitochondrial permeabilization and release of cytochrome 
C. However, it is also known that p53 is frequently mutated in TNBC [325, 326], as is the 
case for the TNBC cell lines used in this thesis. It does not rule out the possibility that 
p53 family members, such as p73, are activated in place of p53 itself, which has been 
shown in the literature.  
Another possibility is that FASN inhibition effects cellular membranes, leading to 
dysfunction of the mitochondria and release of cytochrome C, resulting in apoptosis. A 
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previous paper had shown that knockdown of FASN led to mitochondrial impairment 
and apoptosis [129]. Inhibition of FASN by 5-hydroxy lansoprazole sulfide could alter the 
membrane make-up of the mitochondrial membrane, leaving cells susceptible to 
apoptosis. A previous study revealed that inhibition of FASN led to activation of the 
intrinsic apoptosis pathway, with release of cytochrome c and activation of caspase 3, 
independent of p53, and mitochondrial permeability transition by altering fatty acid 
composition of the mitochondrial membrane [327, 328].  
Additionally, is apoptosis caused by 5-hydroxy lansoprazole sulfide completely 
caspase dependent? Or, are there additional pathways that are activated and culminate 
in cell death? While this thesis indicates that ROS is playing a role in DNA damage, as 5 
mM NAC treatment reduced gH2AX, it is not clear if ROS is playing another role in 
reversing apoptosis outside of DNA damage response. Further studies are needed to 
elucidate whether one or a combined effort of these two mechanisms are leading to 
apoptosis by 5-hydroxy lansoprazole sulfide. 
Necroptosis is another form of cell death that could be occurring after treatment 
with 5-hydroxy lansoprazole sulfide. The flow cytometry graphs in Figures 11, 12 and 18 
indicate that treatment with 5-hydroxy lansoprazole sulfide causes cells to be in late 
apoptosis or necrotic state. This could indicate that cells are going through not just 
apoptosis but also necroptosis. Necroptosis is another form of programmed cell death. 
The main players in cell death by necroptosis are RIPK3 and MLKL [329]. Activation of 
necroptosis is caspase independent and mimics necrosis [330, 331]. 
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To determine what role apoptosis and necroptosis are playing in cell death 
caused by 5-hydroxy lansoprazole sulfide the first experiments to answer this question 
would be to inhibit activation of caspases using a pan-caspase inhibitor and determine if 
cell death is still occurring. If cells are continuing to die even in the presence of caspase 
inhibitors it would indicate that cell death is caspase independent and likely occurring 
through another mechanism. To test for necroptosis cells can be treated with RIPK1 
inhibitor necrostatin-1 [330]. RIPK1 is upstream of RIPK3 activation and inhibition of 
RIPK1 will inhibit the process of necroptosis [329]. In this way necroptosis and apoptosis 
can be analyzed to determine their contribution to cell death by 5-hydroxy lansoprazole 
sulfide. 
 Inhibition of FASN by 5-hydroxy lansoprazole sulfide may also affect other 
cellular membranes besides the mitochondrial membrane. Will 5-hydroxy lansoprazole 
sulfide also affect the fluidity of the membrane and increase penetrance of 
chemotherapeutic drugs as seen previously by inhibiting ACC and FASN [127]? As 
discussed briefly above, will 5-hydroxy lansoprazole sulfide have a synergistic effect 
when used in combination with not only doxorubicin, but also with other DNA damaging 
agents? With the known role of 5-hydroxy lansoprazole sulfide inhibition of NHEJ repair 
and the potential ability of FASN inhibition to increase drug penetrance, the implications 
for future treatment strategies could be significant. To proceed in this direction, these 
pathways and possibilities need further investigation. Moving forward, a mouse model 
of disease will need to be used to determine effect in vivo and to identify if combination 
therapy is effective. To determine the effect that 5-hydroxy lansoprazole sulfide has on 
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cellular membranes mass spectrometry can be utilized to analyze the composition of 
lipids in specific membranes, as was done by Zecchin et al. to analyze the composition 
change in the mitochondria membrane of melanoma cells after orlistat treatment [327]. 
Additionally, since FASN inhibition affects lipid raft formation, lipid rafts on the 
membrane can be analyzed using fluorescent glycol chitosan derivatives [332]. Affecting 
lipid raft formations could have significant implications in cell signaling and survival. 
 Due to the decrease in PARP expression and its role in DNA repair, will 
overexpression of PARP reverse some of the effects observed by 5-hydroxy lansoprazole 
sulfide? This experiment would help to determine the exact mechanism of how 5-
hydroxy lansoprazole sulfide is leading to cell death. If DNA damage is an important 
factor in cell death by 5-hydroxy lansoprazole sulfide then an increase in expression of 
PARP should increase NHEJ repair and decrease DNA damage as was seen previously 
[128]. If PARP overexpression increases NHEJ and reduces DNA damage but cell death is 
still occurring another mechanism, such as changes in cellular membrane structures may 
be the driving force for cell death. These experiments will also help to determine if PARP 
is truly being decreased by treatment or if the decrease is caused by an increase in 
cleavage. If PARP overexpression can reverse damage and apoptosis it could indicate 
that PARP is being decreased by treatment. If, however, it cannot reverse damage and 
apoptosis it may indicate that PARP is being cleaved leading to cell death and that the 
observed decrease is actually due to cleavage and not down regulation. Furthermore, 
inhibition of NHEJ repair by 5-hydroxy lansoprazole sulfide may be an effective way to 
treat cancers with defects in other DNA repair pathways, as discussed briefly above. 
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Expanding these findings to other cancers that may have these same defects or 
overexpression of FASN may lead to advanced treatments.  
 Lastly, there are several ways in which the above thesis could be improved. The 
first being that several of these experiments used a set concentration of drug during 
experimentation. While this is an effective way to show differences in the treatment 
groups it is not necessarily the best. It does not provide a way to easily correlate 
cytotoxic effects with DNA damage and cleavage of proteins. It is difficult to normalize 
findings and directly compare efficacy of the treatment groups and control. In the future 
it would be a good idea to use IC25, IC50, and IC75 values for each treatment. In this way it 
is much easier to compare the effect each drug is having at comparable concentrations 
and correlate cytotoxicity to the observed effects. The use of multiple types of reactive 
oxygen species scavengers to assess the effect on DNA damage and apoptosis should 
have been used in order to rule out the possibility that NAC is reacting with 5-hydroxy 
lansoprazole sulfide. Additionally, other assays should be utilized to confirm FASN 
inhibition. These assays include binding assays, FASN activity assays, and more 
specifically activity assays assessing the TE domain of FASN. While the decrease in free 
fatty acids indicates that 5-hydroxy lansoprazole sulfide is inhibiting FASN it does not 
confirm how this is occurring. Experiments determining how 5-hydroxy lansoprazole 
sulfide is affecting other DNA repair pathways may also provide insight into how DNA 
damage and apoptosis are occurring.  
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